

# 000 TABLES2TRACES: DISTILLING TABULAR DATA TO IM- 001 002 PROVE LLM REASONING IN HEALTHCARE 003 004

005 **Anonymous authors**

006 Paper under double-blind review

## 007 008 ABSTRACT 009

010 Large language models (LLMs) excel at reasoning when fine-tuned on curated  
011 text corpora, but many domains, such as medicine, primarily store knowledge  
012 in structured tabular data. Despite its richness, tabular data has been largely  
013 overlooked as a source of reasoning supervision. Interpreting such data requires  
014 structured, relational reasoning across features and outcomes, not just surface-  
015 level pattern matching. In practice, this mirrors clinical decision making, where  
016 doctors often compare patients with similar characteristics and reason about why  
017 their outcomes diverge. We introduce **Tables2Traces**, the first framework to  
018 enable improved domain-grounded reasoning from raw tabular data by generating  
019 contrastive, case-based reasoning traces for model fine-tuning. This establishes  
020 a new supervision paradigm: converting tabular records, traditionally used only  
021 for prediction, into structured reasoning signals that can serve as an effective new  
022 source of supervision for LLMs. Crucially, this paradigm is orthogonal to text-  
023 based QA supervision: rather than competing with curated corpora, it unlocks an  
024 abundant and low-cost modality that complements existing approaches. Using only  
025 cardiovascular patient records, Tables2Traces yields relative gains of 17.2% on  
026 in-domain MedQA questions and 8.4% out-of-domain, improving accuracy in 15  
027 of 17 clinical categories. On MedMCQA, it achieves a 7.2% relative improvement  
028 and outperforms the base model in 16 of 21 specialties. These gains are driven by  
029 a lightweight and general pipeline that elicits structured reasoning via contrastive  
030 and counterfactual prompts. Compared to training on narrative patient descriptions,  
031 Tables2Traces generalizes more effectively across question types and medical  
032 specialties, showing that even limited tabular data can serve as a scalable and  
033 complementary source of reasoning supervision for LLMs.

## 034 1 INTRODUCTION

035 Large language models (LLMs) have achieved remarkable performance across reasoning tasks, from  
036 multi-step mathematics (Cobbe et al., 2021) to medical question answering (Singhal et al., 2023).  
037 These advances are typically attributed to large-scale pretraining followed by supervised fine-tuning  
038 on datasets already structured as text-based reasoning tasks (Ouyang et al., 2022; Wei et al., 2022).  
039

040 In many domains, however, knowledge is stored in *structured, non-linguistic formats* such as elec-  
041 tronic health records, lab results, insurance claims, finance spreadsheets, or scientific measurements.  
042 Such datasets encode complex relationships and decision logic but lack the textual form required for  
043 LLM fine-tuning (Yin et al., 2020; Liu et al., 2021). Closing this modality gap would unlock the  
044 reasoning signals latent in these data sources.  
045

046 Consider a clinician assessing cardiovascular risk from patient records. A row of clinical features  
047 (e.g, age, LDL, diabetes, blood pressure) supports reasoning such as: “patients over 60 with high  
048 LDL and diabetes are at elevated risk, even if blood pressure is normal.” Clinicians perform this  
049 reasoning intuitively, yet there is currently no systematic way to pass this knowledge to an LLM.  
050 Existing strategies rely on curated QA corpora (Puri et al., 2020), table-embedding models (e.g.,  
051 TaBERT (Yin et al., 2020), TAPEX (Liu et al., 2021)), or lightweight adapters (Li & Liang, 2021; Hu  
052 et al., 2022), but none directly translate raw tabular data into reasoning supervision.

053 This raises two challenges. **(C1) Representation:** how to represent each row of features into a  
coherent format suitable for reasoning while preserving feature relationships.

054 **(C2) Trace elicitation:** how to automatically generate reasoning traces that capture the latent  
 055 knowledge contained in the structured data.  
 056

057 To address C1-C2, we introduce **Tables2Traces**, the first end-to-end framework to transform the latent  
 058 knowledge embedded in tabular data to reasoning traces that can then be used to fine-tune and improve  
 059 an LLM. Our goal is to strengthen domain-grounded clinical reasoning rather than general-purpose  
 060 reasoning; the cross-specialty gains we observe reflect transfer of this domain-grounded signal  
 061 rather than an attempt to improve reasoning broadly. More specifically, Tables2Traces addresses the  
 062 following key research question:

063 Can the latent knowledge embedded in structured tabular data be reformulated into reasoning tasks  
 064 that LLMs can learn from-and does fine-tuning on such synthetic examples improve reasoning in  
 065 both in-domain and out-of-domain settings?

066 Addressing this question offers dual benefits. **For domain experts**, it offers a path to adapt LLMs  
 067 using structured datasets to which they already have access. This is especially valuable in fields like  
 068 medicine, where data privacy and regulatory constraints often prevent data sharing. Practitioners can  
 069 extract reasoning supervision directly from their own tabular data, effectively imbuing LLMs with  
 070 local contextual knowledge.

071 **For the LLM research community**, this approach provides a new and complementary modality  
 072 that contains rich domain knowledge for supervision. Although most fine-tuning datasets are human-  
 073 annotated or LLM-synthesized from existing text corpora (Gururajan et al., 2024), we demonstrate  
 074 that abundant tabular data can also provide useful reasoning supervision. This reframes tabular data  
 075 as a rich and domain-specific supervision source and contributes to the growing data-centric shift in  
 076 LLM development. Crucially, to the best of our knowledge, we are the first to demonstrate that latent  
 077 knowledge encoded in tabular datasets can be reformulated into reasoning tasks that improve LLMs.

078 In doing so, we make the following contributions:

079 **Contributions.** ① **Conceptually:** We introduce a novel LLM supervision paradigm of transforming  
 080 tabular datasets into structured reasoning traces. This introduces a new pathway for domain adaptation  
 081 using data that has traditionally been excluded from LLM training pipelines. Our contribution is  
 082 data-centric: we show that structured tabular records can be transformed into reasoning supervision  
 083 that improves medical QA performance, without introducing new model architectures or optimization  
 084 methods. ② **Methodologically:** We present **Tables2Traces**, a lightweight and modular pipeline  
 085 that generates contrastive questions and multi-step reasoning traces from labeled tabular data, using  
 086 only a small QA subset for output-format alignment. ③ **Empirically:** We evaluate on `MedQA` and  
 087 `MedMCQA`, using 105k synthetic traces and 10k QA examples. `Tables2Traces` yields strong in-domain  
 088 gains (+17.2%) and generalizes out-of-domain (+8.4% on `MedQA`, +7.2% on `MedMCQA`), showcasing  
 089 the effectiveness of tabular supervision. ④ **Analytically:** We find that `Tables2Traces` closes part of  
 090 the gap to a state-of-the-art medical QA model, *Aloe*, while using only around 1.3% as much medical  
 091 QA data. *Aloe* serves as a natural reference point as it exemplifies the standard paradigm for medical  
 092 QA, where performance is driven by large-scale QA-format supervision across many curated medical  
 093 datasets. We show how contrastive supervision improves generalization across question types and  
 094 embedding space regions.

095 **Disclaimer.** The models produced in this work are intended solely for research use; they are not  
 096 designed or validated for clinical decision-making and must not be used for diagnostic or treatment  
 097 purposes.

## 100 2 RELATED WORK

101 This work engages with works on LLM fine-tuning and LLMs for tabular data.

102 **LLM Fine-Tuning.** Prior work demonstrates that fine-tuning LLMs on structured reasoning datasets  
 103 (e.g. `GSM8K`) can significantly improve problem-solving capabilities, which can then be enhanced  
 104 via chain-of-thought prompting (Wei et al., 2022). Instruction-tuning (e.g. `Self-Instruct` (Wang  
 105 et al., 2023b)) further show that training with human-style prompts and reasoning traces enhances  
 106 generalization across unseen tasks. More recently, `DeepSeek-R1` (Guo et al., 2025) introduced  
 107 a large-scale framework for fine-tuning LLMs on curated reasoning traces using the Generalized  
 Reinforcement Preference Optimization (GRPO). By combining diverse, high-quality reasoning

traces with fine-tuning, DeepSeek-R1 demonstrated strong improvements. Our work builds on this paradigm by generating structured reasoning traces not from existing text corpora, but from raw tabular datasets, enabling fine-tuning in domain-specific settings.

In parallel, alignment methods such as reinforcement learning from human feedback (RLHF) (Ouyang et al., 2022), direct preference optimization (DPO) (Rafailov et al., 2023), and reward modeling (Christiano et al., 2017) have shown that models benefit from being tuned on outputs aligned with human preferences. However, all of these methods assume access to a large corpus of natural language examples. In contrast, we synthesize supervision from structured data, which is abundant but underutilized in current LLM pipelines. Our work is orthogonal to these and serves to highlight the potential of structured tabular data as a new source of supervision.

**LLMs for tabular data.** Research on modeling structured tables with language models has largely focused on two paradigms: semantic table understanding and supervised prediction. For the former, models like TABERT (Yin et al., 2020), TAPEX (Liu et al., 2021), and TURL (Deng et al., 2022) learn joint text-table representations for question answering and schema reasoning. For the latter task of prediction, architectures such as TabNet (Arik & Pfister, 2021) and FT-Transformer (Gorishniy et al., 2021) are optimized for predictive modeling over tabular features.

More recently, LLM-based approaches such as TabLLM (Hegselmann et al., 2023), UniPredict (Wang et al., 2023a), LLaMA-GTL (Yan et al., 2024) and TP-BERTa (Zhang et al., 2023) explore serialized tabular inputs or tabular pretraining to improve transferability in tabular prediction tasks.

However, these methods tackle the fundamentally different problem of LLMs understanding tables or LLMs being used as tabular predictors. In contrast, we focus on answering the question of how to use tabular structured data (and the knowledge contained therein) to enhance the reasoning capabilities of LLMs within the relevant problem domain. i.e. how can we use tabular data on cardiovascular patients to improve an LLMs capabilities to reason about cardiovascular problems or even more general medical questions.

### 3 METHOD

#### 3.1 PROBLEM FORMULATION

We assume a tabular dataset  $\mathcal{D} = \{x_1, \dots, x_N\}$  where each row  $x_i \in \mathbb{R}^d$  is a structured record (e.g., a clinical case) and is associated with a binary label  $y_i \in \{0, 1\}$ . While such tabular datasets encode rich domain knowledge, they do not naturally align with the data formats LLMs are typically trained on. We hence seek a mapping that converts this structure into contrastive prompts and structured reasoning traces suitable for supervised fine-tuning of LLMs:

$$\Pi : \mathcal{D} = \{(x_i, y_i)\}_{i=1}^N \longrightarrow \mathcal{C} = \{(P_i, R_i)\}_{i=1}^M \quad (1)$$

where each prompt  $P_i$  describes a clinical scenario in natural language and each trace  $R_i$  is a structured reasoning trace generated by an LLM.

Ultimately, the goal is that fine-tuning a target LLM with parameters  $\Theta$  on  $\mathcal{C}$  (derived from tabular data), can teach the model to learn high-level reasoning behaviors from the structure of the data, without requiring domain-specific logic or annotation. In doing so, this can improve LLM performance on related text-based tasks such as Q&A. To anchor ideas, we hypothesize that eliciting reasoning traces from tabular medical data and then fine-tuning an LLM on these traces should improve an LLM’s capabilities on medical Q&A tasks.

In this work, we primarily focus on the role of medical tabular data, hence our focus is on eliciting clinical reasoning capabilities from a structured medical dataset.

#### 3.2 TABLES2TRACES

We propose Tables2Traces as a framework that realizes this mapping function  $\Pi$ . The underlying algorithm is outlined in Algorithm 1. In particular, it allows us to provide solutions to overcome the challenges of (C1) Representation and (C2) Trace elicitation.

162 **(C1) Representation.** Our first challenge is how to represent the tabular data in a suitable format,  
 163 prior to eliciting reasoning traces. A deterministic encoder  $\phi$  translates each tabular row  $x_i$  into a  
 164 compact textual patient description. Column headers are normalized into human-interpretable phrases  
 165 (e.g.  $\text{ldl\_chol} \rightarrow$  low-density lipoprotein cholesterol), numerical values are rendered with units, and  
 166 missing entries are declared explicitly. Ultimately,  $\phi$  (operationalized with an LLM), transforms  
 167 tabular rows into fluent text-based summaries  $\phi(x_i) = s_i$ . The result is a corpus of textual case  
 168 descriptions  $\mathcal{C}_{\text{simple}} = \{s_i\}_{i=1}^N$ , which we use as training data for the Tables2Traces (simple) variant.  
 169

170 **(C2) Trace Elicitation.** Once we have the data in a suitable, represented textual format, we wish to  
 171 elicit the appropriate knowledge and reasoning from the data. We do so as follows:

172 ▶ *Contrastive Neighbor Selection.* Clinical reasoning frequently involves comparative analysis, i.e.,  
 173 why did this patient die, whereas a similar patient survived? To elicit a similar contrastive reasoning  
 174 for each anchor example  $x_i$ , we retrieve its nearest survivor  $x_i^{(0)}$  and nearest deceased  $x_i^{(1)}$  based  
 175 on the Gower distance <sup>1</sup>, as it respects heterogeneous feature types. We use this to form a narrative  
 176 triplet  $\tau_i = (\phi(x_i^{(0)}), s_i, \phi(x_i^{(1)}))$ , which corresponds to a contrastive decision used as supervision  
 177 for the LLM.

178 ▶ *Reasoning extraction via prompt design.* We wrap each summary  $\tau_i$  in a prompt template  $P_i$   
 179 (Appendix C.3) designed to elicit deeper reasoning about structured differences in the tabular data  
 180 rather than surface-level pattern matching. The design is inspired by ideas from contrastive learning,  
 181 consistency checking, and counterfactual reasoning, adapted into natural-language form so that they  
 182 can serve as supervision for an LLM:

1. **Differential reasoning.** Compare the TARGET to each neighbour and list decisive feature  
 185 differences. This step encourages differential reasoning about relative risk patterns and  
 186 structured comparisons between similar cases.
2. **Label Plausibility.** State whether the recorded outcome is clinically plausible. This step  
 187 promotes a general form of critical evaluation and teaches the model to reason about internal  
 188 consistency rather than simply accept labels at face value.
3. **Counterfactual Planning.** We prompt the model to suggest one *minimal* feature edit that  
 189 would reverse the outcome and justify why. The model must isolate an actionable feature  
 190 (e.g. reduce LDL to  $< 100 \text{ mg/dL}$ ) and explain its physiological effect. This mirrors clinical  
 191 reasoning in which a clinician asks, “What intervention would have saved this patient?”.  
 192 This encourages a higher-level causal reasoning heuristic that goes beyond pattern matching  
 193 and requires identifying features with directional influence.

194 ▶ *Trace Extraction and Corpus Assembly.* We pass the constructed prompt  $P_i$   
 195 to the frozen LLM  $\mathcal{L}$  (e.g. Deepseek-R1) and extract the generated reasoning  
 196 trace  $R_i$ . Collecting every pair yields the corpus  $\mathcal{C}$ , wherein we have  
 197 converted the tabular data into structured reasoning traces.

198 **Supervised Fine-tuning.** We then  
 199 fine-tune a downstream target LLM using  
 200 standard supervised learning on the  
 201 dataset  $\{(P_i, R_i)\}$ . Each training exam-  
 202 ple consists of: **Input:** the contrastive  
 203 prompt  $P_i$  (including the three case de-  
 204 scriptions) and **Output:** the generated  
 205 reasoning trace  $R_i$ .

---

**Algorithm 1** TABLES2TRACES: From Tabular Data to Reasoning Corpus

---

**Require:** Tabular dataset  $D$ , frozen LLM  $\mathcal{L}$

```

1: Output: Reasoning corpus  $\mathcal{C}$ 
2: for each  $(x_i, y_i) \in D$  do
3:    $s_i \leftarrow \phi(x_i)$                                 ▷ Representation
4:   for  $y \in \{0, 1\}$  do
5:      $x_i^{(y)} \leftarrow \arg \min_{x: y_x = y} \text{Gower}(x, x_i)$ 
6:   end for
7:    $\tau_i \leftarrow (\phi(x_i^{(0)}), s_i, \phi(x_i^{(1)}))$  ▷ Contrastive triple
8:    $P_i \leftarrow \pi(\tau_i)$                                 ▷ Compose prompt
9:    $R_i \leftarrow \text{POSTPROCESS}(\mathcal{L}(P_i))$  ▷ Trace elicitation
10:   $\mathcal{C} \leftarrow \mathcal{C} \cup \{(P_i, R_i)\}$ 
11: end for
12: return  $\mathcal{C}$ 

```

---

214 <sup>1</sup>The neighbor-selection step is agnostic to the specific choice of metric, and alternative or learned distance  
 215 functions can be substituted without modifying the overall framework - see Appendix M.

216 We fine-tune the model on a dataset  $\mathcal{R}' = \{(P_i, R_i)\}_{i=1}^M$  consisting of  $M$  prompt–response pairs,  
 217 where each  $P_i$  is a contrastive input prompt and  $R_i$  is the corresponding reasoning trace. 90% of these  
 218 samples are synthetic traces generated from tabular data and 10% are multiple-choice QA-format  
 219 examples (e.g., MedQA). The QA examples were not contained in the evaluation datasets. Training  
 220 on the QA subset alone performs on par with the base model (Appendix L).

221 We hold out 5% of the overall dataset for evaluation. Prompt templates and representative traces are  
 222 shown in Appendices C and D.

223 Let  $\mathcal{L}_{\text{LM}}$  denote the language modeling loss. The fine-tuning objective is then:

$$\min_{\theta} \sum_{(P, R) \in \mathcal{R}'} \mathcal{L}_{\text{LM}}(R \mid P; \theta),$$

228 where  $\theta$  are the parameters of the language model. As Tables2Traces uses standard supervised fine-  
 229 tuning with a fixed architecture, the computational cost scales linearly with the number of reasoning  
 230 traces, and trace generation is a one-time preprocessing step that parallelizes trivially across rows.

232 **Extensibility.** Although we apply the method in a clinical setting with a binary outcome, the  
 233 framework is not restricted to this domain. Tables2Traces assumes only that each row represents a  
 234 coherent and interpretable entity and that a meaningful way to select similar and dissimilar rows exists.  
 235 Clinical datasets naturally satisfy these conditions because each row corresponds to a patient, but other  
 236 domains, such as finance or education, may require different design choices about what constitutes an  
 237 entity and how similarity should be defined. The framework also supports alternative label structures  
 238 in principle, including multi-class or continuous outcomes, by adjusting how neighbors are selected.  
 239 Exploring these extensions is an interesting direction for future work, and our current implementation  
 240 should be viewed as a proof of concept in a domain with well-defined row semantics.

## 241 4 EXPERIMENTS

244 We evaluate Tables2Traces as a mechanism for transforming structured tabular data into effective  
 245 domain-grounded reasoning supervision for LLMs. Our goal is to assess whether this supervision  
 246 improves medical QA performance, and to analyze where performance differences across question  
 247 types, medical domains, and benchmarks.

248 **Data.** We use a subset of the UK Biobank (Sudlow et al., 2015) comprising 105,299 individuals  
 249 aged 40 and above, all diagnosed with cardiovascular disease. Each patient is represented by 32  
 250 variables spanning demographics, medication usage, lab results, and comorbidities. All data were  
 251 collected under appropriate ethical approvals and informed consent (Palmer, 2007).

253 **Setup.** We evaluate two tabular supervision variants: (1) **Tables2Traces (simple)**, which converts  
 254 each row into a standalone patient narrative; and (2) **Tables2Traces**, which adds contrastive prompts  
 255 using nearest-neighbor pairs. Each variant uses 90% synthetic reasoning traces and 10% of syntheti-  
 256 cally generated QA-format examples from HPAI-BSC/MedQA-Mixtral-CoT (Gururajan et al.,  
 257 2024), included only for aligning the model to the multiple-choice answer format. Both Tables2Traces  
 258 variants rely on this same small subset, and ablations confirm that it does not contribute meaningfully  
 259 to performance (Appendix L).

260 We fine-tune both 8 billion parameter (8B) (DeepSeek-R1-Distill-LLaMA-8B) and 7 billion  
 261 (7B) parameter (DeepSeek-R1-Distill-Qwen-7B) models<sup>2</sup> using the Open-R1 framework  
 262 (HuggingFace, 2025). Training configurations are detailed in Appendix B and results for 7B models  
 263 are provided separately in Appendix H.

265 **Evaluation.** We evaluate on two medical QA benchmarks: MedQA (Jin et al., 2021) and  
 266 MedMCQA (Pal et al., 2022). Accuracy is reported under four aggregation schemes (average, best-  
 267 of- $n$ , majority vote, worst-of- $n$ ). Results are averaged over 10 stochastic runs; error bars show the

268  
 269 <sup>2</sup>We consider these smaller model sizes as these are realistic LLM sizes for fine-tuning in clinical settings  
 given compute limitations.

270 standard error of the mean. We compare both fine-tuned variants against a **Base** model without  
 271 fine-tuning.

272 We also report **Aloe** (Gururajan et al., 2024), a strong medical QA system trained with resource-  
 273 intensive, heavily curated supervision across more than twenty datasets (e.g., synthetic chain-of-  
 274 thought, guideline-based answers, adversarial/preference tuning). Importantly, Aloe is *not a reasoning*  
 275 *model*, so it is not aligned with our supervision signal. Our approach is orthogonal: Tables2Traces  
 276 derives reasoning supervision automatically from structured tabular data without manual labels. For  
 277 completeness, we fine-tuned Aloe with Tables2Traces; performance did not improve (Appendix G),  
 278 consistent with this misalignment.

279 All 8B models use the same LLaMA-8B backbone and identical inference settings, and we apply  
 280 identical chain-of-thought prompts at test time (Appendix C.7-C.8). Differences therefore reflect  
 281 supervision rather than prompting. As a qualitative sanity check of the supervision signal, two  
 282 cardiologists independently reviewed 10 randomly sampled traces and confirmed that none received a  
 283 *Concerning* safety rating (Appendix O; protocol in Appendix N).

284 We assess performance across the following dimensions:

- 286 **1. Performance: Are gains consistent across clinical subdomains and benchmarks?**  
 287 Section 4.1 evaluates performance across 18 clinical categories in MedQA and 21 in MedM-  
 288 CQA to identify where training is most effective and whether performance generalizes.
- 289 **2. Domain generalization: What types of questions benefit from tabular supervision?**  
 290 Section 4.2 examines both *domain transfer* (e.g., cardiovascular → neurology) and *format*  
 291 *transfer* (e.g., patient-specific → abstract) to determine what kinds of questions benefit most.
- 292 **3. Locating successes and failures: Where do models succeed or fail in embedding space?**  
 293 Section 4.3 uses UMAP visualizations to localize model performance across semantic  
 294 regions of the question embedding space.
- 295 **4. Upper bound comparison: How does performance compare to a QA-optimized model?**  
 296 Sec. 4.4 compares our method to *Aloe*, a model trained on large-scale QA data, including the  
 297 training set from both MedQA and MedMCQA. This contextualizes how far Tables2Traces  
 298 can go with primarily tabular supervision compared to a task-optimized upper bound.

#### 300 4.1 ARE GAINS CONSISTENT ACROSS CLINICAL SUBDOMAINS AND BENCHMARKS?

301 **Goal.** Assess whether improvements from tabular supervision generalize across diverse clinical  
 302 categories, and whether these gains hold across both MedQA and MedMCQA benchmarks.

303 **Setup.** For MedQA, we assign each question to one of 18 clinical categories using DeepSeek-R1.  
 304 For MedMCQA, we use the dataset assigned category labels and evaluate on the public validation set  
 305 (as the test set is not accessible). We restrict evaluation to questions with a single correct answer  
 306 to ensure consistency with the MedQA setup and to allow for accurate, per-question performance  
 307 analysis.

308 **Results.** As shown in Table 1 and Appendix E, Tables2Traces consistently outperforms the base  
 309 model across a majority of clinical categories in both datasets. On MedQA, we observe improvements  
 310 in 16 out of 18 categories (89%), with the largest relative gains in *Renal/Genitourinary* (+29.65%),  
 311 *Hematologic* (+18.98%), and *Cardiovascular* (+17.21%). On MedMCQA, Tables2Traces improves  
 312 performance in 16 out of 21 categories (76%), including strong gains in *Psychiatry* (+31.71%), *ENT*  
 313 (+16.56%), and *Anatomy* (+11.91%). Categories showing drops in performance e.g., *Skin* (-24.39%)  
 314 and *Orthopaedics* (-15.00%) have very few test samples ( $N = 11$  and  $N = 15$ ), making these  
 315 estimates statistically unreliable.

316 **Takeaway.** Tables2Traces yields robust, cross-domain improvements on both benchmarks, improving  
 317 in over 80% of clinical categories. The few observed declines are isolated to small and noisy subsets.

#### 320 4.2 WHAT TYPES OF QUESTIONS BENEFIT FROM TABULAR SUPERVISION?

321 **Goal.** To assess whether supervision derived from a single clinical domain (cardiovascular) and a  
 322 single input style (patient-specific reasoning traces) can improve performance on both out-of-domain  
 323 specialties and abstract medical knowledge.

324 Table 1: Per-category evaluation metrics on the MedQA benchmark for Base and Tables2Traces.  
325

Category	Model Type	Avg Accuracy	Best-of-n	Majority Vote	Worst-of-n	% Change
<b>Cardiovascular</b> ( <i>N</i> = 130)	Base	0.40 ± 0.03	0.86 ± 0.03	0.31 ± 0.04	<b>0.06 ± 0.02</b>	
	Tables2Traces	<b>0.47 ± 0.03</b>	<b>0.91 ± 0.03</b>	<b>0.42 ± 0.04</b>	<b>0.06 ± 0.02</b>	<b>+17.21% ↑</b>
<b>Dermatologic</b> ( <i>N</i> = 17)	Base	0.59 ± 0.08	<b>0.94 ± 0.06</b>	0.53 ± 0.12	0.06 ± 0.06	
	Tables2Traces	<b>0.60 ± 0.08</b>	0.88 ± 0.08	<b>0.59 ± 0.12</b>	<b>0.12 ± 0.08</b>	<b>+0.99% ↑</b>
<b>Endocrine/Metabolic</b> ( <i>N</i> = 179)	Base	0.49 ± 0.03	0.89 ± 0.02	0.45 ± 0.04	<b>0.13 ± 0.03</b>	
	Tables2Traces	<b>0.51 ± 0.02</b>	<b>0.91 ± 0.02</b>	<b>0.46 ± 0.04</b>	0.10 ± 0.02	<b>+4.71% ↑</b>
<b>Gastrointestinal</b> ( <i>N</i> = 86)	Base	0.47 ± 0.04	0.87 ± 0.04	0.40 ± 0.05	<b>0.12 ± 0.04</b>	
	Tables2Traces	<b>0.50 ± 0.04</b>	<b>0.91 ± 0.03</b>	<b>0.47 ± 0.05</b>	0.08 ± 0.03	<b>+6.72% ↑</b>
<b>Hematologic</b> ( <i>N</i> = 68)	Base	0.40 ± 0.04	0.84 ± 0.04	0.34 ± 0.06	0.04 ± 0.03	
	Tables2Traces	<b>0.48 ± 0.04</b>	<b>0.91 ± 0.04</b>	<b>0.43 ± 0.06</b>	<b>0.07 ± 0.03</b>	<b>+18.98% ↑</b>
<b>Immunologic</b> ( <i>N</i> = 81)	Base	0.51 ± 0.04	0.85 ± 0.04	<b>0.47 ± 0.06</b>	<b>0.22 ± 0.05</b>	
	Tables2Traces	<b>0.54 ± 0.04</b>	<b>0.94 ± 0.03</b>	0.46 ± 0.06	0.17 ± 0.04	<b>+6.80% ↑</b>
<b>Infectious</b> ( <i>N</i> = 176)	Base	0.48 ± 0.03	0.92 ± 0.02	0.41 ± 0.04	<b>0.11 ± 0.02</b>	
	Tables2Traces	<b>0.53 ± 0.02</b>	<b>0.94 ± 0.02</b>	<b>0.45 ± 0.04</b>	<b>0.11 ± 0.02</b>	<b>+9.73% ↑</b>
<b>Musculoskeletal</b> ( <i>N</i> = 45)	Base	0.49 ± 0.05	0.89 ± 0.05	<b>0.49 ± 0.07</b>	0.04 ± 0.03	
	Tables2Traces	<b>0.51 ± 0.04</b>	<b>0.96 ± 0.03</b>	0.40 ± 0.07	<b>0.07 ± 0.04</b>	<b>+4.07% ↑</b>
<b>Neurological</b> ( <i>N</i> = 77)	Base	0.47 ± 0.04	0.86 ± 0.04	0.42 ± 0.06	0.09 ± 0.03	
	Tables2Traces	<b>0.54 ± 0.04</b>	<b>0.95 ± 0.03</b>	<b>0.48 ± 0.06</b>	<b>0.14 ± 0.04</b>	<b>+15.15% ↑</b>
<b>Obstetrics/Gynecology</b> ( <i>N</i> = 70)	Base	0.46 ± 0.04	0.90 ± 0.04	0.39 ± 0.06	<b>0.09 ± 0.03</b>	
	Tables2Traces	<b>0.47 ± 0.03</b>	<b>0.94 ± 0.03</b>	<b>0.40 ± 0.06</b>	0.03 ± 0.02	<b>+2.80% ↑</b>
<b>Oncology</b> ( <i>N</i> = 72)	Base	0.53 ± 0.04	0.92 ± 0.03	0.47 ± 0.06	0.11 ± 0.04	
	Tables2Traces	<b>0.56 ± 0.04</b>	<b>0.93 ± 0.03</b>	<b>0.53 ± 0.06</b>	<b>0.14 ± 0.04</b>	<b>+5.82% ↑</b>
<b>Other</b> ( <i>N</i> = 31)	Base	<b>0.53 ± 0.07</b>	0.77 ± 0.08	<b>0.45 ± 0.09</b>	<b>0.23 ± 0.08</b>	
	Tables2Traces	0.50 ± 0.07	<b>0.87 ± 0.06</b>	0.42 ± 0.09	0.19 ± 0.07	<b>-4.88% ↓</b>
<b>Pediatric</b> ( <i>N</i> = 13)	Base	<b>0.39 ± 0.09</b>	0.77 ± 0.12	<b>0.39 ± 0.14</b>	<b>0.00 ± 0.00</b>	
	Tables2Traces	<b>0.39 ± 0.05</b>	<b>1.00 ± 0.00</b>	0.31 ± 0.13	<b>0.00 ± 0.00</b>	<b>-1.96% ↓</b>
<b>Psychiatric</b> ( <i>N</i> = 52)	Base	0.59 ± 0.05	<b>0.94 ± 0.03</b>	0.54 ± 0.07	<b>0.23 ± 0.06</b>	
	Tables2Traces	<b>0.62 ± 0.05</b>	0.90 ± 0.04	<b>0.61 ± 0.07</b>	0.21 ± 0.06	<b>+5.57% ↑</b>
<b>Renal/Genitourinary</b> ( <i>N</i> = 54)	Base	0.37 ± 0.04	0.85 ± 0.05	0.26 ± 0.06	0.04 ± 0.03	
	Tables2Traces	<b>0.48 ± 0.04</b>	<b>0.96 ± 0.03</b>	<b>0.41 ± 0.07</b>	<b>0.09 ± 0.04</b>	<b>+29.65% ↑</b>
<b>Respiratory</b> ( <i>N</i> = 54)	Base	0.49 ± 0.04	0.91 ± 0.04	0.43 ± 0.07	0.09 ± 0.04	
	Tables2Traces	<b>0.50 ± 0.04</b>	<b>0.94 ± 0.03</b>	<b>0.46 ± 0.07</b>	<b>0.11 ± 0.04</b>	<b>+2.28% ↑</b>
<b>Toxicology</b> ( <i>N</i> = 68)	Base	0.43 ± 0.04	0.79 ± 0.05	0.41 ± 0.06	0.06 ± 0.03	
	Tables2Traces	<b>0.52 ± 0.04</b>	<b>0.91 ± 0.04</b>	<b>0.47 ± 0.06</b>	<b>0.09 ± 0.04</b>	<b>+20.68% ↑</b>
<b>Overall</b> ( <i>N</i> = 1273)	Base	0.47 ± 0.01	0.88 ± 0.01	0.41 ± 0.01	0.11 ± 0.01	
	Tables2Traces	<b>0.51 ± 0.01</b>	<b>0.93 ± 0.01</b>	<b>0.46 ± 0.01</b>	<b>0.10 ± 0.01</b>	<b>+9.19% ↑</b>

**Setup.** We assess generalization along two axes: (1) **Domain**—partitioning questions into *cardiovascular* vs. *non-cardiovascular* using model-inferred labels; and (2) **Format**—classifying questions as *patient-specific* or *abstract*, based on whether they describe concrete cases (e.g., 45-year-old man) or general concepts. MedQA is predominantly patient-specific (92.3%), while MedMCQA is mostly abstract (83.7%) (see Appendix F).

**Results.** In MedQA, Tables2Traces shows strong gains on in-domain (cardiovascular, +17.2%) and patient-specific questions (+10.0%), with smaller gains on abstract questions (+1.8%) (Figure 1). However, Tables2Traces (simple) performs worse on abstract questions (−15.3%), possibly suggesting overfitting to training format. In MedMCQA, we observe broader generalization: Tables2Traces improves both patient-specific (+6.8%) and abstract (+7.6%) subsets.

**Takeaway.** Tabular supervision supports generalization beyond its source domain and format. Without counterfactual reasoning, tabular supervision can overfit to its patient-specific training data, resulting in performance degradation in out-of-domain tasks. With counterfactual reasoning, Tables2Traces improves performance even on abstract, unfamiliar questions. These gains on abstract questions, where no patient structure is present, indicate that the model is not relying on patient-specific memorization but has learned higher-level, domain-specific reasoning heuristics introduced by the structured supervision.




Figure 1: Accuracy comparison across model variants. Subplots show mean accuracy on MedQA and MedMCQA, with error bars for standard error. Percentages indicate improvement over the Base model. Top row: in-domain (cardiovascular, patient-specific); bottom row: out-of-domain (non-cardiovascular, abstract).

#### 4.3 WHERE DO MODELS SUCCEED OR FAIL IN EMBEDDING SPACE?

**Goal.** Visualize how supervision strategies impact the semantic generalization of medical questions.

**Setup.** We embed all MedQA and MedMCQA questions using `text-embedding-3-large` (OpenAI, 2023) and reduce dimensionality via UMAP. Each point corresponds to a question, colored by clinical category. Background shading shows smoothed relative accuracy of the fine-tuned model compared to the **Base** model. Figure 2 shows two panels: (a) **Tables2Traces**, and (b) **Tables2Traces (simple)**. A complementary plot for MedMCQA is provided in Appendix E.

**Results.** Both models show localized gains within the cardiovascular region. However, only Tables2Traces generalizes effectively across distant clusters whereas the patient-style model (b) overfits to regions that closely resemble its training format. Peripheral zones, often containing abstract or non-patient-centered questions (e.g., *Biochemistry*, *Social Medicine*), show degradation under the simple model but improved performance under Tables2Traces. These patterns mirror our quantitative results and extend to the MedMCQA visualization.

**Takeaway.** Contrastive reasoning traces lead to broader semantic generalization, increasing performance across diverse question types and topics. In contrast, models trained only on patient description data tend to overfit and struggle in abstract or semantically distant regions of the question space.

#### 4.4 HOW DOES PERFORMANCE COMPARE TO A QA-OPTIMIZED MODEL?

**Goal.** To benchmark Tables2Traces against a strong QA-tuned model, we compare it to **Aloe**—a state-of-the-art medical LLM trained on over 750,000 medical QA pairs from datasets including MedQA and MedMCQA, and further optimized through preference and adversarial feedback tuning (Gururajan et al., 2024). Rather than a direct competitor, Aloe represents a *task-optimized upper bound* built from large-scale QA supervision. Our comparison asks how far Tables2Traces can go using primarily tabular reasoning traces and only a small amount of QA data.

**Setup.** We evaluate **Base**, **Tables2Traces**, and **Aloe** across four subsets: *cardiovascular*, *non-cardiovascular*, *patient-specific*, and *abstract*, using both MedQA and MedMCQA (Figure 3). Aloe




Figure 2: UMAP visualization of MedQA test questions comparing model performance to the **Base** model. Each point is a question, embedded using `text-embedding-3-large` (OpenAI, 2023), and annotated by medical category using distinct marker shapes and colors. Accuracy is smoothed using a Gaussian filter ( $\sigma = 1.5$ ). The background heatmap shows relative performance: red indicates improvement, blue indicates degradation. Cluster labels mark category centroids. **(a)** Tables2Traces achieves broad gains across much of the question space. **(b)** Tables2Traces (simple) yields localized improvements, but also shows notable drops in performance in several regions.

is trained on nearly one million QA-format medical examples (human and synthetic), whereas Tables2Traces uses only about 10k QA-format examples for alignment and relies primarily on 105k reasoning traces generated from tabular data.

**Results.** As expected, Aloe achieves the highest accuracy in all categories. However, Tables2Traces closes a substantial portion of the gap despite using only 1.3% of the QA supervision data used by Aloe. The remaining supervision comes from synthetic reasoning traces, which incur no annotation cost. On MedQA, Tables2Traces improves +17.2% on cardiovascular questions (vs. Aloe’s +26.0%) and +9.6% on patient-specific questions (vs. +25.3%). In MedMCQA, Tables2Traces achieves +10.6% and +6.8% improvements on cardiovascular and patient-specific questions respectively. Notably, even Aloe shows limited gains on abstract, non-patient-specific questions across both benchmarks, suggesting these are structurally more challenging and underrepresented during training.

**Takeaway.** **Tables2Traces achieves strong generalization with minimal QA supervision.** Despite being trained using *75x fewer medical QA samples* compared to Aloe, our approach closes a substantial portion of the performance gap. This highlights the value of clinical reasoning traces from tabular data as a scalable, interpretable, and cost-effective alternative to large-scale QA corpora.

## 5 DISCUSSION

Tables2Traces provides a scalable approach for converting structured tabular data into contrastive reasoning traces and improves LLM performance on medical QA tasks even when trained on a single clinical domain. Trace generation is a one-time preprocessing step that can be reused across




Figure 3: Accuracy comparison between **Base**, **Tables2Traces**, and **Aloe** across question categories, grouped by benchmark (MedMCQA, MedQA). Each subplot reports mean accuracy with standard error bars. Percentage improvements are relative to the **Base** model. Top row: in-domain categories. Bottom row: out-of-domain generalization.

models, and in practice fine-tuning dominates the total compute. By leveraging structured clinical data, the method introduces a new and broadly applicable source of supervision that encourages domain-specific higher-level reasoning behaviors grounded in patient differences. Importantly, our objective is to study domain-grounded reasoning supervision rather than general-purpose reasoning.

Although all training tabular data comes from a cardiovascular cohort, the model improves performance across many unrelated medical specialties. This suggests that the reasoning signal transfers beyond the training domain. The contrast between the simple and full variants supports this interpretation. Both variants use the same underlying tabular records and the same QA alignment subset, yet the simple version degrades on multiple out-of-domain subsets while the full version improves. This indicates that the gains arise from the structured reasoning components rather than from specialty-specific correlations in the tabular data or the QA alignment subset.

**Tables2Traces** provides an explicit and inspectable supervision signal: each fine-tuning example includes a structured reasoning trace that researchers can review and analyze. This transparency may support interpretability research during model development, since the training-time reasoning distribution is observable rather than implicit. However, these traces are not clinical explanations and should not be used for medical decision-making. Their interpretability value is limited to understanding the supervision signal itself rather than conferring interpretability at inference time.

As our clinician review indicates, the traces can omit relevant context or exhibit overconfident interpretations because they are based on limited structured features rather than full patient histories. Any biases present in the underlying observational dataset may also propagate into the synthetic traces and the resulting model. These traces are therefore intended solely as a research supervision signal rather than as clinically validated explanations. Combining synthetic reasoning with expert-curated or hybrid supervision represents a promising direction for improving fidelity in future work. More broadly, while tabular supervision can make domain adaptation more accessible, it also inherits any biases present in the underlying dataset. Ensuring the fidelity and safety of synthetic traces in real-world settings remains an important follow-up direction beyond the scope of this study. Additionally, systematically studying how performance varies with the amount of tabular supervision as well as identifying other sources of synthetic supervision are important avenues for future research.

540  
541  
**ETHICS STATEMENT**

542 This work uses de-identified UK Biobank data accessed under approved use; all participants provided  
 543 informed consent and data collection was overseen by the UK Biobank ethics framework. Our  
 544 method, Tables2Traces, generates synthetic reasoning traces from structured records to fine-tune  
 545 language models for research purposes only. The models and traces are *not* clinical devices and  
 546 must not be used for diagnosis or treatment. To gauge plausibility and safety, two cardiologists  
 547 qualitatively reviewed 10 randomly sampled traces independently using a structured rubric. Clinician  
 548 review confirmed no safety concerns but did note overconfidence by the model, reflecting the inherent  
 549 limitations of synthetic data. The cardiology experts noted that outcomes may depend on factors not  
 550 present in the tabular snapshot; our traces are therefore positioned as research-only supervision signals,  
 551 not calibrated risk assessments or clinical guidance. We provide an overview of their comments in  
 552 Appendix O. We release prompts and code to support auditability. Finally, our evaluation is restricted  
 553 to public medical QA benchmarks and does not involve individual-level deployment or decision  
 554 support.

555  
556 **REPRODUCIBILITY STATEMENT**

557 All implementation details, prompts, hyperparameters, and evaluation procedures are documented  
 558 in the Appendix. Upon acceptance we will release the full codebase and configs to reproduce  
 559 preprocessing, trace generation, fine-tuning, and evaluation, together with exact seeds and scripts that  
 560 render all tables and figures. Results on public benchmarks (MedQA, MedMCQA) are reproducible  
 561 with our released scripts and seeds. UK Biobank data cannot be shared; researchers with approved  
 562 access can regenerate the training traces using our scripts and instructions.

563  
564 **REFERENCES**

565  
 566 Sercan Ö Arik and Tomas Pfister. Tabnet: Attentive interpretable tabular learning. In *Proceedings of*  
 567 *the AAAI conference on artificial intelligence*, volume 35, pp. 6679–6687, 2021.

568  
 569 Paul F Christiano, Jan Leike, Tom Brown, Miljan Martic, Shane Legg, and Dario Amodei. Deep  
 570 reinforcement learning from human preferences. *Advances in neural information processing*  
 571 *systems*, 30, 2017.

572 Karl Cobbe, Vineet Kosaraju, Mohammad Bavarian, Mark Chen, Heewoo Jun, Lukasz Kaiser,  
 573 Matthias Plappert, Jerry Tworek, Jacob Hilton, Reiichiro Nakano, et al. Training verifiers to solve  
 574 math word problems. *arXiv preprint arXiv:2110.14168*, 2021.

575  
 576 Xiang Deng, Huan Sun, Alyssa Lees, You Wu, and Cong Yu. Turl: Table understanding through  
 577 representation learning. *ACM SIGMOD Record*, 51(1):33–40, 2022.

578  
 579 Yury Gorishniy, Ivan Rubachev, Valentin Khrulkov, and Artem Babenko. Revisiting deep learning  
 580 models for tabular data. *Advances in neural information processing systems*, 34:18932–18943,  
 2021.

581  
 582 Daya Guo, Dejian Yang, Huawei Zhang, Junxiao Song, Ruoyu Zhang, Runxin Xu, Qihao Zhu,  
 583 Shirong Ma, Peiyi Wang, Xiao Bi, et al. Deepseek-r1: Incentivizing reasoning capability in llms  
 584 via reinforcement learning. *arXiv preprint arXiv:2501.12948*, 2025.

585  
 586 Ashwin Kumar Gururajan, Enrique Lopez-Cuena, Jordi Bayarri-Planas, Adrian Tormos, Daniel  
 587 Hinjos, Pablo Bernabeu-Perez, Anna Arias-Duart, Pablo Agustin Martin-Torres, Lucia Urcelay-  
 588 Ganzabal, Marta Gonzalez-Mallo, et al. Aloe: A family of fine-tuned open healthcare llms.  
 589 *arXiv preprint arXiv:2405.01886*, 2024.

590  
 591 Stefan Heggemann, Alejandro Buendia, Hunter Lang, Monica Agrawal, Xiaoyi Jiang, and David  
 592 Sontag. Tabllm: Few-shot classification of tabular data with large language models. In *International  
 593 Conference on Artificial Intelligence and Statistics*, pp. 5549–5581. PMLR, 2023.

594  
 595 Edward J Hu, Yelong Shen, Phillip Wallis, Zeyuan Allen-Zhu, Yuanzhi Li, Shean Wang, Lu Wang,  
 596 Weizhu Chen, et al. Lora: Low-rank adaptation of large language models. *ICLR*, 1(2):3, 2022.

594 HuggingFace. Open r1: A fully open reproduction of deepseek-r1, January 2025. URL <https://github.com/huggingface/open-r1>.

595

596

597 Di Jin, Eileen Pan, Nassim Oufattolle, Wei-Hung Weng, Hanyi Fang, and Peter Szolovits. What

598 disease does this patient have? a large-scale open domain question answering dataset from medical

599 exams. *Applied Sciences*, 11(14):6421, 2021.

600 Xiang Lisa Li and Percy Liang. Prefix-tuning: Optimizing continuous prompts for generation. *arXiv*

601 preprint [arXiv:2101.00190](https://arxiv.org/abs/2101.00190), 2021.

602 Qian Liu, Bei Chen, Jiaqi Guo, Morteza Ziyadi, Zeqi Lin, Weizhu Chen, and Jian-Guang Lou. Tapex:

603 Table pre-training via learning a neural sql executor. *arXiv preprint arXiv:2107.07653*, 2021.

604

605 OpenAI. Openai text-embedding-3-large, 2023. <https://platform.openai.com/docs/guides/embeddings>.

606

607 Long Ouyang, Jeffrey Wu, Xu Jiang, Diogo Almeida, Carroll Wainwright, Pamela Mishkin, Chong

608 Zhang, Sandhini Agarwal, Katarina Slama, Alex Ray, et al. Training language models to follow

609 instructions with human feedback. *Advances in neural information processing systems*, 35:27730–

610 27744, 2022.

611

612 Ankit Pal, Logesh Kumar Umapathi, and Malaikannan Sankarasubbu. Medmcqa: A large-scale

613 multi-subject multi-choice dataset for medical domain question answering. In *Conference on*

614 *health, inference, and learning*, pp. 248–260. PMLR, 2022.

615 Lyle J Palmer. Uk biobank: bank on it. *The Lancet*, 369(9578):1980–1982, 2007.

616

617 Raul Puri, Ryan Spring, Mostofa Patwary, Mohammad Shoeybi, and Bryan Catanzaro. Training

618 question answering models from synthetic data. *arXiv preprint arXiv:2002.09599*, 2020.

619 Rafael Rafailov, Archit Sharma, Eric Mitchell, Christopher D Manning, Stefano Ermon, and Chelsea

620 Finn. Direct preference optimization: Your language model is secretly a reward model. *Advances*

621 in *Neural Information Processing Systems*, 36:53728–53741, 2023.

622

623 Karan Singhal, Shekoofeh Azizi, Tao Tu, S Sara Mahdavi, Jason Wei, Hyung Won Chung, Nathan

624 Scales, Ajay Tanwani, Heather Cole-Lewis, Stephen Pfahl, et al. Large language models encode

625 clinical knowledge. *Nature*, 620(7972):172–180, 2023.

626

627 Cathie Sudlow, John Gallacher, Naomi Allen, Valerie Beral, Paul Burton, John Danesh, Paul Downey,

628 Paul Elliott, Jane Green, Martin Landray, et al. Uk biobank: an open access resource for identifying

629 the causes of a wide range of complex diseases of middle and old age. *PLoS medicine*, 12(3):

630 e1001779, 2015.

631 Ruiyu Wang, Zifeng Wang, and Jimeng Sun. Unipredict: Large language models are universal tabular

632 classifiers. *arXiv preprint arXiv:2310.03266*, 2023a.

633 Yizhong Wang, Yeganeh Kordi, Swaroop Mishra, Alisa Liu, Noah A Smith, Daniel Khashabi, and

634 Hannaneh Hajishirzi. Self-instruct: Aligning language models with self-generated instructions. In

635 *Proceedings of the 61st Annual Meeting of the Association for Computational Linguistics (Volume*

636 *1: Long Papers)*, pp. 13484–13508, 2023b.

637 Jason Wei, Xuezhi Wang, Dale Schuurmans, Maarten Bosma, Fei Xia, Ed Chi, Quoc V Le, Denny

638 Zhou, et al. Chain-of-thought prompting elicits reasoning in large language models. *Advances in*

639 *neural information processing systems*, 35:24824–24837, 2022.

640 Jiahuan Yan, Bo Zheng, Hongxia Xu, Yiheng Zhu, Danny Z Chen, Jimeng Sun, Jian Wu, and

641 Jintai Chen. Making pre-trained language models great on tabular prediction. *arXiv preprint*

642 *arXiv:2403.01841*, 2024.

643 Pengcheng Yin, Graham Neubig, Wen-tau Yih, and Sebastian Riedel. Tabert: Pretraining for joint

644 understanding of textual and tabular data. In *Proceedings of the 58th Annual Meeting of the*

645 *Association for Computational Linguistics*, pp. 8413–8426, 2020.

646

647 Han Zhang, Xumeng Wen, Shun Zheng, Wei Xu, and Jiang Bian. Towards foundation models for

learning on tabular data. 2023.

648  
649

## APPENDIX

650  
651

## A EVALUATION SETUP

652

We use a standardized evaluation pipeline across all models and benchmarks. Each multiple-choice question is formatted using the appropriate chat template (e.g., using standard templates like `AutoTokenizer.apply_chat_template`) and fed into the model for completion. Evaluation is performed using the `vLLM` framework with sampling-based generation (`temperature=0.6`, `top_p=0.85`, `n=3` completions per prompt, `frequency_penalty=1.5`, `presence_penalty=0.9`, `max_tokens=32768`). We extract the final answer (A–D) from the generated output using robust regex-based parsing, and fall back to the reasoning text if a clean answer is not present after multiple attempts.

660

We stop generation using model-specific stop tokens (e.g., `</s>` for LLaMA, `<|EOT|>` for Qwen), as well as answer-format strings (e.g., "Answer: A"). All completions are post-processed using a training-aware cleaner to remove template artifacts (e.g., "Assistant: " headers). For models fine-tuned on structured reasoning traces, we additionally parse the `<think>...</think>` block and extract the final prediction from the trailing answer segment.

665

The pipeline includes automatic retries for failed generations, and safely extracts answers even under high sampling variability. This setup ensures consistent evaluation across all models and supports multi-sample decoding strategies such as best-of- $n$ , majority vote, and worst-of- $n$ .

668

## A.1 EVALUATION METRICS

669  
670

All performance metrics are aggregated from 10 independent inference runs per model. For each test question, we collect a binary correctness label (extracted using a robust regex-based parsing) for each of the 10 completions and compute the following evaluation metrics:

671

- **Average Accuracy:** The average correctness across the 10 runs for each question.
- **Best-of- $n$ :** The question is marked correct if at least one of the 10 completions is correct.
- **Majority Vote:** The question is marked correct if a majority of the 10 completions are correct. In the case of a tie, the outcome defaults to incorrect.
- **Worst-of- $n$ :** The question is marked correct only if all 10 completions are correct.

681

Category-level and overall scores are computed by averaging across all test questions per category. Error bars represent the standard error of the mean (SEM) across test examples. Additionally, we report the relative percent change in average accuracy compared with the Base model. In all results tables, the best-performing model is shown in bold for each metric within each category. If multiple models have the same value after rounding, all are shown in bold.

686

687

688

689

690

691

692

693

694

695

696

697

698

699

700

701

702 B TRAINING CONFIGURATION DETAILS  
703704 All models are fine-tuned using Open-R1’s supervised fine-tuning pipeline (HuggingFace, 2025),  
705 with a single epoch of training on 4xA100 80GB GPUs. We use FlashAttention-2 and  
706 bfloat16 precision for all experiments. Below, we describe shared configurations and model-  
707 specific differences.  
708709 B.1 SHARED CONFIGURATION  
710

- **Precision:** bfloat16 with FlashAttention-2
- **Epochs:** 1 full pass over the training set
- **Batch Size:** 2 per device, 8 gradient accumulation steps
- **Optimizer:** AdamW with learning rate =  $5e-6$ , cosine decay (min LR ratio = 0.1), weight decay = 0.0001
- **Max Sequence Length:** 32,768 tokens
- **Evaluation:** Every 500 steps on the test split
- **Checkpointing:** Saved every 500 steps, keep only latest
- **Logging:** Via wandb, every 5 steps
- **Seed:** 42
- **Gradient Checkpointing:** Enabled (non-reentrant)
- **System Prompt:**

725 You are a helpful AI Assistant that provides  
726 well-reasoned and detailed responses.  
727 You first think about the reasoning process as an internal monologue  
728 and then provide the user with the answer.  
729 Respond in the following format:  
730 <think> ... </think>  
731 <answer> ... </answer>

- **Chat Template:** Modified to include reasoning tags (<think>...</think>) in the completion and exclude them from the prefill.

756 B.2 MODEL VARIANTS  
757758 We fine-tune two architectures on two dataset variants, resulting in four total models:  
759

761 Model Architecture	761 Training Data
762 DeepSeek-R1-Distill-Qwen-7B	Patient Descriptions (Tables2Traces (simple))
763 DeepSeek-R1-Distill-Qwen-7B	Counterfactual Traces (Tables2Traces)
764 DeepSeek-R1-Distill-Llama-8B	Patient Descriptions (Tables2Traces (simple))
765 DeepSeek-R1-Distill-Llama-8B	Counterfactual Traces (Tables2Traces)

766  
767 The **patient descriptions** dataset consists of direct narrative renderings of individual tabular rows,  
768 while the **counterfactual traces** dataset includes contrastive triplets with structured reasoning (as  
769 described in Section 3). All datasets are processed using 48 parallel workers.  
770771 Table 2: Training runtimes for each model variant.  
772

773 Model Variant	773 Architecture	773 Runtime
775 Tables2Traces	8B (LLaMA)	20h 37m
776 Tables2Traces (simple)	8B (LLaMA)	9h 24m
777 Tables2Traces	7B (Qwen)	19h 52m
778 Tables2Traces (simple)	7B (Qwen)	9h 18m

781 C PROMPT TEMPLATES  
782783 This section documents all prompt templates used during dataset construction, training, and evalua-  
784 tion. Strings enclosed in curly brackets (e.g., {column\_names}) represent placeholders that are  
785 dynamically replaced with instance-specific values at runtime, similar to Python f-strings.  
786

## 788 C.1 COLUMN NAME MAPPING (TABLE REPRESENTATION)

789 **Purpose:** Transform raw or abbreviated column headers into clinically accurate feature names.  
790791 **Placeholders:** column\_names is replaced with a list of all columns of the dataset.  
792794 Column Name Mapping  
795

796 You are a powerful AI with expertise in medicine.  
797 You are given a dataset with columns that relate to patients where each patient is a row  
798 and each column contains different information pertaining to the patient.

800 As your first task, you are tasked with converting a list of column names that are  
801 possibly abbreviated or not easy to understand into a fully understandable name for  
802 medical professionals.  
803 Please provide the output as a Python dictionary.

804 The list of column names is: {column\_names}

805 C.2 PATIENT DESCRIPTION GENERATION  
806807 **Purpose:** Convert structured patient rows into fluent narrative case descriptions.  
808809 **Placeholders:** json\_file is replaced with a json-file containing the column names as keys and  
the values of columns as values.

810  
 811  
 812 You are a powerful AI with expertise in medicine.  
 813 Your task is to generate a detailed and exhaustive text description for a patient.  
 814 You are given all the patient information in a json-format, which contains the clinical attributes  
 815 and the results from laboratory tests from real world patients.  
 816 The patients in question are patients with cardiovascular disease.  
 817 The reader of the description is an expert within this particular medical domain.  
 818 The language used in the description should reflect your domain expertise  
 819 and your medical reasoning capabilities.  
 820 Please provide as many details as possible.  
 821 You should ONLY include the patient description!

820  
 821  
 822  
 823  
 824  
 825 The json-file containing the information from the patient: {json\_file}

### C.3 CONTRASTIVE REASONING AND COUNTERFACTUAL TRACES

825 **Purpose:** Generate reasoning traces comparing a target patient to contrasting neighbors.

826  
 827 **Placeholders:** target\_outcome is the outcome (Alive / Dead) for the target patient.  
 828 survivor\_description is the text description of the nearest neighbor to the target patient  
 829 who had the outcome "Alive". survivor\_description is the text description of the nearest  
 830 neighbor to the target patient who had the outcome "Dead". target\_description is the text  
 831 description target patient. All text descriptions are derived using the Patient Description Generation  
 832 prompt in Appendix C.2.

### Counterfactual Task Generation

833  
 834  
 835     ### Role ###  
 836     Clinical AI analyzing patient outcomes using contrastive case pairs.  
 837  
 838     ### Input Data ###  
 839     1) Target patient (labeled {target\_outcome})  
 840     2) Nearest neighbor who survived  
 841     3) Nearest neighbor who died  
 842  
 843     ==== CLOSEST SURVIVOR ====  
 844     {survivor\_description}  
 845     ==== CLOSEST DEATH ====  
 846     {death\_description}  
 847     ==== TARGET PATIENT ====  
 848     {target\_description}  
 849  
 850     ### Required Analysis ###  
 851     1. Comparison:  
 852         a) Identify 1-3 decisive differences between target and NNs  
 853         b) Focus on features present in ALL THREE cases  
 854         c) Flag any conflicting evidence  
 855  
 856     2. Label Evaluation:  
 857         a) Assess if {target\_outcome} is correct  
 858         b) Confidence score (1-5)  
 859  
 860     3. Counterfactual:  
 861         a) Modify one feature present in NNs  
 862         b) Predict outcome change  
 863         c) Justify using specific NN evidence  
 864  
 865     ### Response Format ###  
 866     1. Comparison:  
 867         1) Outcome alignment: <...>  
 868         2) Decisive factors: ...  
 869  
 870     2. Label assessment:  
 871         1) Correctness: <...>  
 872         2) Confidence: <...>  
 873  
 874     3. Counterfactual:  
 875         1) Modification: <...>  
 876         2) Outcome: <...>  
 877         3) Evidence: <...>

864 C.4 CATEGORIZATION: PATIENT-SPECIFIC VS. ABSTRACT  
865866 **Purpose:** Categorize questions as either patient-specific or abstract.867 **Placeholders:** question is the specific question to be categorized.868  
869 Patient-specific Categorization  
870

```

871 You are a clinical reasoning expert.
872 Your task is to determine whether a multiple-choice medical question is *patient-specific*.
873
874 Definitions:
875 - A question is **patient-specific** if it describes
876 a particular patient case -- including their symptoms, medical history, age, lab results, etc.
877 These questions simulate real-life clinical decision-making.
878 - A question is **not patient-specific** if it
879 asks about general medical knowledge or includes references to people (e.g., doctors, nurses)
880 but *not to a patient's condition*.
881
882 Return: {"patient_specific": true} or {"patient_specific": false}
883
884 Examples:
885
886 Example 1:
887 Question: A 67-year-old man presents with sudden chest pain and shortness of breath.
888 Which of the following is the most likely diagnosis?
889 Answer: {"patient_specific": true}
890
891 Example 2:
892 Question: What is the most common cause of mitral stenosis worldwide?
893 Answer: {"patient_specific": false}
894
895 Example 3:
896 Question: A physician enters the operating room without washing his hands.
897 What is the correct protocol in this situation?
898 Answer: {"patient_specific": false}
899
900 ---
```

901 Now classify the following question:

902 Question: {question}

903 Answer:

## 895 C.5 CATEGORIZATION: CARDIOVASCULAR VS. NON-CARDIOVASCULAR (MEDMCQA)

896 **Purpose:** Categorize MedMCQA questions as either cardiovascular related or not.897 **Placeholders:** question is the specific question to be categorized.900  
901 Cardiovascular Categorization  
902

```

903 You are a medical assistant helping categorize medical questions.
904 Given a question, determine whether it pertains to cardiovascular diseases or not.
905
906 Only answer 'true' or 'false' depending on whether the core topic of the question
907 involves cardiovascular systems, diseases, symptoms, diagnostics, or treatment.
908 Cardiovascular topics include (but are not limited to) conditions such as: hypertension,
909 myocardial infarction, arrhythmias, heart failure, atherosclerosis, angina, or cardiac arrest.
910
911 Avoid false positives: questions mentioning blood pressure, heart rate, or medications like
912 beta-blockers must still be relevant to cardiovascular context to count.
913
914 Output your answer in the following JSON format:
915
916 {"cardiovascular_related": true}
917
918 Question:
919 {question}
```

## 915 C.6 CATEGORIZATION: MEDICAL DOMAIN (MEDQA)

916 **Purpose:** Categorize the medical domain of MedQA questions.

918  
919**Placeholders:** question is the specific question to be categorized.920  
921

## Medical Domain Categorization

922  
923

Analyze the medical question and respond EXACTLY as follows:

924  
925

---STRICT RULES---

1. SINGLE HIGH-CONFIDENCE CATEGORY ( $\geq 0.7$ ):• If ONE category scores  $\geq 0.7$ :

"Category = Score"

• If MULTIPLE categories score  $\geq 0.7$ :

Choose ONLY THE HIGHEST SCORE (if tie, pick first alphabetically)

926  
9272. MULTIPLE LOW-CONFIDENCE CATEGORIES (all  $< 0.7$ ):

• "Primary: Category1 = Score1, Secondary: Category2 = Score2, Tertiary: Category3 = Score3"

928  
929

3. IRRELEVANT:

• "None of the above = 1.0"

930  
931

---VALID EXAMPLES---

• "Cardiovascular = 0.85"

• "Primary: Infectious = 0.6, Secondary: Hematologic = 0.3, Tertiary: Renal = 0.1"

• "None of the above = 1.0"

932  
933

---CATEGORIES (ALPHABETICAL ORDER)---

Cardiovascular, Dermatologic, Endocrine/Metabolic, Gastrointestinal, Hematologic,

Immunologic, Infectious, Musculoskeletal, Neurological, Obstetrics/Gynecology,

Oncology, Pediatric, Psychiatric, Renal/Genitourinary, Respiratory, Toxicology

934  
935

---QUESTION---

{question}

936  
937

---YOUR RESPONSE (MUST MATCH EXACTLY ONE FORMAT ABOVE)---

938  
939940  
941942  
943944  
945946  
947948  
949950  
951952  
953954  
955956  
957958  
959960  
961962  
963964  
965966  
967968  
969970  
971

972 C.7 EVALUATION PROMPTS: MEDQA  
973974 **Purpose:** Evaluate model on MedQA using reasoning-aware prompting.  
975976 **MedQA Evaluation Prompt**

```

977     **Role**: You are a medical knowledge expert.
978     **Task**: Analyze the following multiple-choice medical question by following these steps:
979     1. First, use critical clinical reasoning to think about the question
980         step-by-step before giving a final answer.
981     2. After completing your reasoning, directly provide your final answer.
982     3. **IMPORTANT**: Do not provide any explanation beyond your answer in the final output.

983     **Response Format**:
984     [Your step-by-step reasoning goes here]
985     Answer: [Your final choice: A, B, C, or D]

```

986 C.8 EVALUATION PROMPTS: MEDMCQA  
987988 **Purpose:** Evaluate model on MedMCQA using structured reasoning steps.  
989990 **MedMCQA Evaluation Prompt**

```

991     **Role**: You are a medical knowledge expert.
992     **Task**: Analyze the following multiple-choice medical question by reasoning
993         step-by-step before selecting the best answer.

994     Follow these steps:
995     1. Identify the topic and relevant concepts.
996     2. Recall or infer medical knowledge needed to solve the question.
997     3. Eliminate incorrect options and justify your final choice.
998     4. Provide your answer clearly and concisely.

999     **Response Format**:
1000     [Step-by-step reasoning]
1001     Answer: [A, B, C, or D]

1002     **Constraints**:
1003     - Do not explain anything after giving your final answer.
1004     - Only choose a single option from A-D.

```

1005

1006

1007

1008

1009

1010

1011

1012

1013

1014

1015

1016

1017

1018

1019

1020

1021

1022

1023

1024

1025

1026 **D QUALITATIVE EXAMPLES**  
1027  
1028  
1029  
1030

1031 This section provides representative examples of reasoning traces generated during training and  
1032 evaluation. These examples illustrate the structure, fluency, and clinical plausibility of model outputs  
1033 for both Tables2Traces and Tables2Traces (simple). All examples are drawn directly from the training  
1034 data without curation or filtering. Specifically, the example shown here (both the patient description  
1035 task and the counterfactual task) corresponds to the first available row in the dataset and is included  
1036 with minimal editing beyond redaction for privacy.

1040 **D.1 QUALITATIVE EXAMPLE: PATIENT DESCRIPTION REASONING (REDACTED)**  
1041  
1042  
1043

1044 We include a representative example of a reasoning trace generated from a single patient description  
1045 prompt. The input data has been redacted for privacy, but the structure of the trace is preserved. The  
1046 resulting model response corresponds to the training data used for the Tables2Traces (simple) variant  
1047 and as the generated patient descriptions used for generating the counterfactual tasks.

1051 **Patient JSON Input (Redacted)**  
1052  
1053

1054 You are a powerful AI with expertise in medicine. Your task is to generate a detailed and exhaustive text description for a patient.  
1055 You are given all the patient information in a json-format, which contains the clinical attributes and the results from laboratory tests  
1056 from real world patients. The patients in question are patients with cardiovascular disease. The reader of the description is an expert  
1057 within this particular medical domain. The language used in the description should reflect your domain expertise and your medical  
1058 reasoning capabilities. Please provide as many details as possible. You should ONLY include the patient description!

1059 The json-file containing the information from the patient:

1060 Sex	...
1061 Age (Years)	...
1062 Weight (Kilograms)	...
1063 Height (Centimeters)	...
1064 Smoking Amount (Cigarettes per Day)	...
1065 Atrial Fibrillation Diagnosis	...
1066 Chronic Kidney Disease Diagnosis	...
1067 Rheumatoid Arthritis Diagnosis	...
1068 Anti-diabetic Medication Use	...
1069 Anti-hypertensive Medication Use	...
1070 Diabetes History	...
1071 Lipid-lowering Medication Use	...
1072 Oral Contraceptive Use	...
1073 Blood Glucose Level (mmol/L)	...
1074 Hemoglobin A1c (HbA1c) Percentage	...
1075 White Blood Cell Count ( $\times 10^9/L$ )	...
1076 Serum Creatinine ( $\mu\text{mol}/L$ )	...
1077 Triglyceride Level (mmol/L)	...
1078 Uric Acid Level ( $\mu\text{mol}/L$ )	...
1079 Cystatin C Level (mg/L)	...
Systolic Blood Pressure (mmHg)	...
Urine Microalbumin Concentration (mg/L)	...
C-Reactive Protein (CRP) Level (mg/L)	...
Family History of Cardiovascular Disease (CVD)	...
Atypical Antipsychotic Medication Use	...
Corticosteroid Medication Use	...
Migraine History	...
Severe Mental Illness Diagnosis	...
Systemic Lupus Erythematosus (SLE) Diagnosis	...
Total Cholesterol Level (mmol/L)	...
High-Density Lipoprotein (HDL) Cholesterol Level (mmol/L)	...
Ethnicity	...

1080  
1081

## Model Reasoning (Redacted)

1082  
1083  
1084  
1085  
1086

<think> Okay, let's start by going through all the patient data provided. The patient is a [...] -year-old [...] [...] with a height of [...] cm and weight of [...] kg. Calculating his BMI: weight divided by height squared in meters. So [...] kg / [...] m<sup>2</sup> = [...] kg/m<sup>2</sup>. That puts him in the overweight category, which is a risk factor for cardiovascular issues.

1087  
1088  
1089  
1090

He's a smoker, [...] cigarettes per day. That's significant. Smoking is a major risk factor for cardiovascular diseases, including atherosclerosis and hypertension. His systolic blood pressure is [...] mmHg, which is way above the normal range. Stage 2 hypertension. But he's not on anti-hypertensive meds, which is concerning. Uncontrolled hypertension can lead to heart failure, stroke, etc.

1091  
1092  
1093  
1094

Looking at his lab results. Blood glucose is [...] mmol/L, which is within normal fasting levels. HbA1c is [...]%, also normal, so no indication of diabetes. No history of diabetes either. So glucose metabolism seems okay. But his lipid profile: total cholesterol [...] mmol/L, which is a bit elevated. Triglycerides at [...] mmol/L, which is borderline high. HDL is [...] mmol/L, which is on the lower side for males. Low HDL and elevated triglycerides could contribute to atherosclerosis. But he's not on lipid-lowering meds, so that's another risk factor not being managed.

1095  
1096  
1097  
1098

Serum creatinine is [...] µmol/L. Using the CKD-EPI equation for eGFR. For a [...] -year-old [...], serum creatinine of [...] converts to an eGFR around [...] mL/min/...m<sup>2</sup>, which is normal. Cystatin C is [...] mg/L, which also correlates with normal kidney function. Urine microalbumin is [...] mg/L, which is within normal range. So no signs of chronic kidney disease, which aligns with the CKD diagnosis being [...].

1099  
1100  
1101  
1102

CRP is [...] mg/L, which is normal. Low CRP suggests no significant inflammation. No rheumatoid arthritis, SLE, or other inflammatory conditions. Uric acid is [...] µmol/L. Normal range for males is around 416, so his is within normal. Not a hyperuricemia case, so less concern for gout.

1103  
1104  
1105

He has atrial fibrillation (diagnosis 1), which is a major risk for stroke and heart failure. Given his age and hypertension, that's a critical factor. No family history of CVD, so maybe environmental factors like smoking and hypertension are the main contributors here. No other comorbidities like severe mental illness or migraines.

1106  
1107  
1108

Other meds: Not on anti-diabetics, lipid-lowering, or antihypertensives. So his AFib and hypertension are untreated, which is alarming. His high systolic BP could be exacerbating the atrial fibrillation, increasing stroke risk. The CHA<sub>2</sub>DS<sub>2</sub>-VASc score would be [...], indicating anticoagulation should be considered.

1109  
1110  
1111  
1112

In summary, this patient has multiple modifiable risk factors: smoking, obesity, uncontrolled hypertension, dyslipidemia. The presence of atrial fibrillation without anticoagulation or rate control meds significantly elevates his thromboembolic risk. The absence of diabetes or kidney disease is a positive note, but the untreated hypertension and smoking are critical areas needing intervention. His elevated systolic BP is a key driver for cardiovascular events. Management should focus on smoking cessation, initiating antihypertensive therapy, lipid management, and evaluating for anticoagulation given his AFib. </think>

1113  
1114  
1115

## Model Response (Redacted)

1116  
1117  
1118

The patient is a [...] -year-old [...] [...] with a body mass index (BMI) of [...] kg/m<sup>2</sup> (height: [...] cm; weight: [...] kg), categorizing him as overweight. He reports a significant smoking history of [...] cigarettes/day, a critical modifiable cardiovascular risk factor. Key clinical findings include \*\*stage [...] hypertension\*\* (systolic blood pressure: [...] mmHg) without current anti-hypertensive therapy, \*\*atrial fibrillation\*\* (diagnosis confirmed), and a lipid profile suggestive of mixed dyslipidemia (total cholesterol: [...] mmol/L, triglycerides: [...] mmol/L, HDL-C: [...] mmol/L). Notably, his LDL-C (calculated via Friedewald equation: [...] mmol/L) exceeds optimal targets, yet he is not on lipid-lowering therapy.

1119  
1120  
1121  
1122

Metabolically, he exhibits normoglycemia (fasting glucose: [...] mmol/L; HbA1c: [...]%) without evidence of diabetes or anti-diabetic medication use. Renal function is preserved (serum creatinine: [...] µmol/L; eGFR > [...] mL/min/...m<sup>2</sup> by CKD-EPI; cystatin C: [...] mg/L; urine microalbumin: [...] mg/L), ruling out chronic kidney disease. Inflammatory markers are unremarkable (CRP: [...] mg/L), with no history of autoimmune or systemic inflammatory conditions. Uric acid levels [...] µmol/L are within normal limits, mitigating concern for gout-related contributions.

1123  
1124  
1125  
1126

The absence of anti-hypertensive or anticoagulant therapy in the setting of atrial fibrillation and severe hypertension raises immediate concern for thromboembolic risk (CHA<sub>2</sub>DS<sub>2</sub>-VASc score  $\leq$  [...] ) and hypertensive end-organ damage. His lipid abnormalities—elevated triglycerides, low HDL-C, and borderline-high LDL-C—suggest residual atherogenic risk despite normal BMI-adjusted adiposity metrics. The combination of smoking, untreated hypertension, and dyslipidemia synergistically amplifies his cardiovascular risk profile, warranting aggressive risk factor modification.

1127  
1128  
1129  
1130

No family history of CVD or secondary causes of hypertension (e.g., renal, endocrine) is documented. The absence of diabetes, chronic kidney disease, or inflammatory comorbidities narrows the primary drivers of his cardiovascular pathology to lifestyle factors (smoking, diet) and age-related vascular stiffening. Urgent interventions should prioritize smoking cessation, BP control (target  $<130/80$  mmHg per ACC/AHA guidelines), statin initiation, and atrial fibrillation management with anticoagulation and rhythm control strategies.

## D.2 QUALITATIVE EXAMPLE: COUNTERFACTUAL REASONING (REDACTED)

1131  
1132  
1133

We include a representative example of a reasoning trace generated from a counterfactual reasoning trace for the first row of the dataset. The input data has been redacted for privacy, but the structure of the trace is preserved. This format corresponds to the Tables2Traces variant. For readability, the input to the counterfactual task is shown in three parts. In practice, the full prompt is passed to the LLM as a single string. The split here is purely for presentation purposes.

1134  
 1135 Counterfactual Input (Redacted) - Part 1

1136     ### Role ###  
 1137     Clinical AI analyzing patient outcomes using contrastive case pairs.

1138     ### Input Data ###  
 1139     1) Target patient (labeled Dead)  
 1140     2) Nearest neighbor who survived  
 1141     3) Nearest neighbor who died

1142     ==== CLOSEST SURVIVOR ====  
 1143     \*\*Patient Description\*\*  
 1144     The patient is a \*\*[...]\*\*-year-old [...] male\*\*  
 1145     with a body mass index (BMI) of \*\*[...] kg/m^2\*\* (weight: [...] kg,  
 1146     height: [...] cm)), categorizing him as \*\*overweight\*\*,  
 1147     a significant modifiable risk factor for cardiovascular disease (CVD).  
 1148     He reports a \*\*[...]\*\*-cigarette/day smoking history\*\*, a major independent risk factor  
 1149     for atherosclerotic CVD and thromboembolic events.

1150     \*\*Cardiovascular and Comorbidity Profile\*\*:  
 1151     - \*\*Atrial fibrillation (AF)\*\* is confirmed (diagnosis code present),  
 1152     elevating his risk of thromboembolic complications, including stroke.  
 1153     - \*\*No diabetes mellitus\*\* (HbA1c: [...]%, fasting glucose: [...] mmol/L)  
 1154     or chronic kidney disease (CKD) (serum creatinine: [...] mumol/L,  
 1155     cystatin C: [...] mg/L, urine microalbumin: [...] mg/L).  
 1156     - \*\*Uncontrolled hypertension\*\* (systolic BP: [...] mmHg) is evident, with no current use  
 1157     of anti-hypertensive medications, suggesting suboptimal risk factor management.  
 1158     - \*\*Hyperlipidemia\*\* is present (total cholesterol: [...] mmol/L, HDL: [...] mmol/L,  
 1159     triglycerides: [...] mmol/L), with an estimated LDL-C of \*\*[...] mmol/L\*\* (Friedewald equation),  
 1160     indicative of significant dyslipidemia.  
 1161     Despite this, no lipid-lowering therapy is documented.

1162     \*\*Inflammatory and Metabolic Markers\*\*:  
 1163     - \*\*C-reactive protein (CRP)\*\* is within normal limits ([...] mg/L),  
 1164     suggesting no acute systemic inflammation.  
 1165     - \*\*Uric acid\*\* levels are borderline elevated ([...] mumol/L),  
 1166     though below the threshold for clinical hyperuricemia.

1167     \*\*Additional Risk Stratification\*\*:  
 1168     - \*\*No family history of CVD\*\*, autoimmune disease (e.g., rheumatoid arthritis, SLE),  
 1169     or severe mental illness.  
 1170     - \*\*Absence of diabetic, antihypertensive, or lipid-lowering pharmacotherapy\*\*  
 1171     highlights potential undertreatment of modifiable CVD risk factors.

1172     \*\*Clinical Synthesis\*\*:  
 1173     This patient presents with \*\*high-risk cardiovascular profile\*\* driven by \*\*age, smoking, untreated hypertension, and significant hypercholesterolemia\*\*, compounded by \*\*AF-related thromboembolic risk\*\*. The absence of diabetes or CKD does not mitigate his overall risk, as his ASCVD (atherosclerotic cardiovascular disease) risk score would likely place him in a high-risk category. Urgent interventions should prioritize \*\*smoking cessation, BP control (target <130/80 mmHg per guidelines), and statin therapy\*\* (high-intensity statin indicated for LDL-C reduction >50%). \*\*Anticoagulation for AF\*\* (CHA\_2DS\_2-VASC score  $\geq 2$  given age  $\geq [...]$  and hypertension) should be evaluated to mitigate stroke risk. Close monitoring of renal function (cystatin C-based eGFR) and lipid profiles is warranted to guide therapeutic efficacy and adherence.

1174  
 1175  
 1176  
 1177  
 1178  
 1179  
 1180  
 1181  
 1182  
 1183  
 1184  
 1185  
 1186  
 1187

1188  
1189

## Counterfactual Input (Redacted) - Part 2

1190  
1191  
1192  
1193  
1194  
1195  
1196

==== CLOSEST DEATH ====  
 The patient is a [...] -year-old [...] male with a body mass index (BMI) of [...] kg/m<sup>2</sup> (weight: [...] kg, height: [...] cm), categorizing him as overweight. He is an active smoker with a significant tobacco exposure of [...] cigarettes/day, a major independent risk factor for atherosclerotic cardiovascular disease (ASCVD). His medical history is notable for atrial fibrillation (AFib), a critical arrhythmia conferring a 5-fold increased risk of thromboembolic events, but no evidence of chronic kidney disease (CKD), diabetes mellitus (DM), or autoimmune disorders.

1197  
1198  
1199  
1200  
1201  
1202  
1203

\*\*Cardiometabolic Profile:\*\*  
 - \*\*Hypertension:\*\* Uncontrolled stage 2 hypertension (systolic BP: [...] mmHg) without current antihypertensive therapy. This elevates his 10-year ASCVD risk substantially, particularly when combined with smoking.  
 - \*\*Lipid Abnormalities:\*\* Borderline-high total cholesterol [...] mmol/L with elevated calculated LDL-C (~ [...] mmol/L via Friedewald equation) and suboptimal HDL-C [...] mmol/L, consistent with atherogenic dyslipidemia. Triglycerides are within normal limits [...] mmol/L.  
 - \*\*Glycemic Status:\*\* Normoglycemic (fasting glucose: [...] mmol/L; HbA1c: [...] %), excluding DM.

1204  
1205  
1206  
1207

\*\*Renal & Inflammatory Markers:\*\*  
 - Preserved renal function: Serum creatinine [...] µmol/L (eGFR ~ [...] mL/min/[...]m<sup>2</sup> by CKD-EPI), cystatin C [...] mg/L, and normoalbuminuria (urine microalbumin: [...] mg/L).  
 - Mild systemic inflammation: CRP [...] mg/L, potentially reflecting endothelial dysfunction from smoking or subclinical atherosclerosis.

1208  
1209  
1210  
1211

\*\*Additional Risk Stratification:\*\*  
 - Absence of protective factors: No lipid-lowering, antihypertensive, or anticoagulant use despite AFib and ASCVD risk factors.  
 - No familial predisposition to CVD or contributory medication use (e.g., corticosteroids, antipsychotics).

1212  
1213  
1214  
1215  
1216  
1217  
1218  
1219

\*\*Clinical Implications:\*\*  
 This patient exhibits a high-risk phenotype for ASCVD and thromboembolism due to the confluence of modifiable factors: smoking, untreated hypertension, dyslipidemia, and AFib. The absence of diabetes or CKD does not mitigate this risk, as his SCORE2-Diabetes equation-adjusted 10-year CVD risk likely exceeds 10%. Urgent interventions should include smoking cessation, BP control (target <130/80 mmHg per ACC/AHA guidelines), high-intensity statin therapy (e.g., atorvastatin 40-80 mg), and CHA<sub>2</sub>DS<sub>2</sub>-VASc-guided anticoagulation for AFib. Weight optimization and serial monitoring of inflammatory markers (e.g., CRP) and cardiac troponins could further refine prognostication.

1220  
1221  
1222  
1223  
1224  
1225  
1226  
1227  
1228

==== TARGET PATIENT ====  
 The patient is a [...] -year-old [...] male with a body mass index (BMI) of [...] kg/m<sup>2</sup> (height: [...] cm; weight: [...] kg), categorizing him as overweight. He reports a significant smoking history of [...] cigarettes/day, a critical modifiable cardiovascular risk factor. Key clinical findings include \*\*stage 2 hypertension\*\* (systolic blood pressure: [...] mmHg) without current anti-hypertensive therapy, \*\*atrial fibrillation\*\* (diagnosis confirmed), and a lipid profile suggestive of mixed dyslipidemia (total cholesterol: [...] mmol/L, triglycerides: [...] mmol/L, HDL-C: [...] mmol/L). Notably, his LDL-C (calculated via Friedewald equation: [...] mmol/L) exceeds optimal targets, yet he is not on lipid-lowering therapy.

1229  
1230  
1231  
1232  
1233

Metabolically, he exhibits normoglycemia (fasting glucose: [...] mmol/L; HbA1c: [...] %) without evidence of diabetes or anti-diabetic medication use. Renal function is preserved (serum creatinine: [...] µmol/L; eGFR > [...] mL/min/[...] by CKD-EPI; cystatin C: [...] mg/L; urine microalbumin: [...] mg/L), ruling out chronic kidney disease. Inflammatory markers are unremarkable (CRP: [...] mg/L), with no history of autoimmune or systemic inflammatory conditions. Uric acid levels [...] µmol/L are within normal limits, mitigating concern for gout-related contributions.

1234  
1235  
1236  
1237  
1238  
1239  
1240  
1241

The absence of anti-hypertensive or anticoagulant therapy in the setting of atrial fibrillation and severe hypertension raises immediate concern for thromboembolic risk (CHA<sub>2</sub>DS<sub>2</sub>-VASc score >=2) and hypertensive end-organ damage. His lipid abnormalities--elevated triglycerides, low HDL-C, and borderline-high LDL-C--suggest residual atherogenic risk despite normal BMI-adjusted adiposity metrics. The combination of smoking, untreated hypertension, and dyslipidemia synergistically amplifies his cardiovascular risk profile, warranting aggressive risk factor modification.

1242  
1243

## Counterfactual Input (Redacted) - Part 3

1244  
1245  
1246  
1247  
1248  
1249

No family history of CVD or secondary causes of hypertension (e.g., renal, endocrine) is documented. The absence of diabetes, chronic kidney disease, or inflammatory comorbidities narrows the primary drivers of his cardiovascular pathology to lifestyle factors (smoking, diet) and age-related vascular stiffening. Urgent interventions should prioritize smoking cessation, BP control (target <130/80 mmHg per ACC/AHA guidelines), statin initiation, and atrial fibrillation management with anticoagulation and rhythm control strategies.

1250  
1251  
1252  
1253

## ### Required Analysis ###

1. Comparison:
  - a) Identify 1-3 decisive differences between target and NNs
  - b) Focus on features present in ALL THREE cases
  - c) Flag any conflicting evidence (e.g., "Target aligns with NN1 in [X] but NN2 in [Y]")

1254  
1255  
1256  
1257  
1258  
1259

2. Label Evaluation:
  - a) Assess if Dead is correct
  - b) Confidence score (1-5):
    - 5 = All evidence strongly agrees
    - 4 = Most evidence agrees
    - 3 = Mixed evidence
    - 2 = Minimal supporting evidence
    - 1 = No discernible pattern

1260  
1261  
1262  
1263

3. Counterfactual:
  - a) Modify one feature present in NNs
  - b) Predict outcome change
  - c) Justify using specific NN evidence

1264  
1265  
1266  
1267

## ### Response Format ###

1. Comparison:
  - 1) Outcome alignment: <Matches Survivor/Matches Death/Uncertain>
  - 2) Decisive factors:
    - 1) <Feature>: Target vs NN1 vs NN2
    - 2) <Feature>: Target vs NN1 vs NN2
2. Label assessment:
  - 1) Correctness: <Correct/Incorrect/Edge Case>
  - 2) Confidence: <1-5 with brief rationale>
3. Counterfactual:
  - 1) Modification: <Feature + change>
  - 2) Outcome: <Survived/Died>
  - 3) Evidence: <"Matches [NN] where [feature]=[value]">

1274  
1275  
1276  
1277

1. Quality Rules:
  - If confidence =<2, state: "Uncertain because [reason]"
  - Counterfactuals must reference features actually present in NNs
  - Use original feature names from input data

1278  
1279  
1280  
1281  
1282  
1283  
1284  
1285  
1286  
1287  
1288  
1289  
1290  
1291  
1292  
1293  
1294  
1295

1296  
1297

## Model Reasoning (Redacted)

1298  
1299  
1300  
1301

<think> Okay, let's start by looking at the three patients: the target who died, the closest survivor (NN1), and the closest death (NN2). All three are [...] males in their [...], overweight, with a [...]-cigarette/day smoking history, atrial fibrillation, uncontrolled hypertension, and untreated hyperlipidemia. They also don't have diabetes or CKD.

1302  
1303

First, comparing the target to the survivor and the other deceased. The target's systolic BP is [...] mmHg, which is higher than both NN1 [...] and NN2 [...]. That's a big difference. High BP is a major risk factor, so maybe the target's much higher BP contributed to his death.

1304  
1305

Next, looking at LDL-C levels. The target's LDL is [...] mmol/L, which is lower than NN1's [...] but higher than NN2's [...]. Wait, NN2's LDL was [...], so the target is actually lower than NN2. Hmm, but the survivor had the highest LDL. That's conflicting. Maybe LDL isn't the decisive factor here.

1306  
1307

Triglycerides: Target has [...], which is higher than both NN1 [...] and NN2 [...]. Elevated triglycerides can contribute to cardiovascular risk, so this might be a key difference. The target's higher triglycerides could have increased his risk compared to the other two.

1308  
1309

So the main differences are systolic BP and triglycerides. The target's BP is the highest, and his triglycerides are higher than both NNs. Even though his LDL is in between, the other factors might be more critical.

1310

For the label assessment, the target died. Both NNs had similar profiles but the target's BP and triglycerides are worse. The survivor had lower BP and lower triglycerides, while the deceased had lower BP than the target. So the higher BP in the target might explain the death. The confidence is high because BP and triglycerides are significant risk factors, and the target's values are worse.

1311  
1312

For the counterfactual, if we lower the target's systolic BP to [...] mmHg (like NN1), maybe he would have survived. NN1 had lower BP and survived, so reducing BP to that level might change the outcome. Alternatively, lowering triglycerides to match NN1 or NN2 could also help, but BP seems more directly impactful. The evidence from NN1 shows that with lower BP, survival occurred despite other risks. </think>

1313  
1314

## Model Response (Redacted)

1315

### 1. Comparison:

1316

1) \*\*Outcome alignment\*\*: Matches Death

1317

2) \*\*Decisive factors\*\*:

1318

1) \*\*Systolic BP\*\*: Target ([...] mmHg) > NN1 ([...] mmHg) > NN2 ([...] mmHg)  
 - Target's severe hypertension (stage 2) exceeds both NNs,  
 increasing acute cardiovascular event risk (e.g., stroke, myocardial infarction).

1319

2) \*\*Triglycerides\*\*: Target ([...] mmol/L) > NN2 ([...] mmol/L) > NN1 ([...] mmol/L)  
 - Elevated triglycerides in the target suggest greater

1320

residual atherogenic risk despite comparable LDL-C levels.

1321

### 2. Label assessment:

1322

1) \*\*Correctness\*\*: Correct

1323

2) \*\*Confidence\*\*: 4/5

1324

- Rationale: The target's \*\*higher systolic BP\*\* and \*\*triglycerides\*\* align with worse outcomes. Both NNs had lower BP and triglycerides, yet the target died. However, conflicting evidence exists in LDL-C

1325

(target: [...] mmol/L vs. NN1: [...] mmol/L),  
 where the survivor paradoxically had higher LDL-C. This reduces confidence to 4.

1326

### 3. Counterfactual:

1327

1) \*\*Modification\*\*: Reduce systolic BP to [...] mmHg (NN1's level)

1328

2) \*\*Outcome\*\*: Survived

1329

3) \*\*Evidence\*\*: Matches \*\*NN1\*\* where systolic BP=[...] mmHg (untreated but lower than target's [...] mmHg). NN1 survived despite similar AFib, smoking, and untreated

1330

hyperlipidemia, suggesting BP control is a pivotal survivability factor.

1331

1332

1333

1334

1335

1336

1337

1338

1339

1340

1341

1342

1343

1344

1345

1346

1347

1348

1349

Table 3: Per-category evaluation metrics on MedMCQA for Base and Tables2Trace (8B).

Category	Model Type	Avg Accuracy	Best-of-n	Majority Vote	Worst-of-n	% Change
<b>Anaesthesia</b> ( <i>N</i> = 24)	Base	<b>0.36 ± 0.07</b>	<b>0.88 ± 0.07</b>	<b>0.29 ± 0.09</b>	<b>0.08 ± 0.06</b>	<b>-1.15% ↓</b>
	Tables2Traces	<b>0.36 ± 0.07</b>	0.83 ± 0.08	<b>0.29 ± 0.09</b>	<b>0.08 ± 0.06</b>	
<b>Anatomy</b> ( <i>N</i> = 147)	Base	0.36 ± 0.02	<b>0.86 ± 0.03</b>	0.26 ± 0.04	0.02 ± 0.01	<b>+11.91% ↑</b>
	Tables2Traces	<b>0.40 ± 0.02</b>	<b>0.88 ± 0.03</b>	<b>0.31 ± 0.04</b>	<b>0.07 ± 0.02</b>	
<b>Biochemistry</b> ( <i>N</i> = 122)	Base	0.57 ± 0.03	0.90 ± 0.03	<b>0.58 ± 0.04</b>	0.11 ± 0.03	<b>+3.62% ↑</b>
	Tables2Traces	<b>0.59 ± 0.03</b>	<b>0.95 ± 0.02</b>	0.56 ± 0.05	<b>0.17 ± 0.03</b>	
<b>Dental</b> ( <i>N</i> = 845)	Base	0.35 ± 0.01	0.82 ± 0.01	0.26 ± 0.02	0.05 ± 0.01	<b>+9.24% ↑</b>
	Tables2Traces	<b>0.39 ± 0.01</b>	<b>0.88 ± 0.01</b>	<b>0.28 ± 0.02</b>	<b>0.06 ± 0.01</b>	
<b>ENT</b> ( <i>N</i> = 39)	Base	0.39 ± 0.05	<b>0.92 ± 0.04</b>	0.26 ± 0.07	<b>0.08 ± 0.04</b>	<b>+16.56% ↑</b>
	Tables2Traces	<b>0.45 ± 0.05</b>	<b>0.92 ± 0.04</b>	<b>0.36 ± 0.08</b>	<b>0.08 ± 0.04</b>	
<b>Forensic Medicine</b> ( <i>N</i> = 44)	Base	<b>0.41 ± 0.05</b>	<b>0.89 ± 0.05</b>	<b>0.32 ± 0.07</b>	0.09 ± 0.04	<b>-1.10% ↓</b>
	Tables2Traces	<b>0.41 ± 0.05</b>	<b>0.89 ± 0.05</b>	0.30 ± 0.07	<b>0.14 ± 0.05</b>	
<b>Gynaecology &amp; Obstetrics</b> ( <i>N</i> = 154)	Base	0.40 ± 0.03	0.81 ± 0.03	0.32 ± 0.04	<b>0.09 ± 0.02</b>	<b>+4.03% ↑</b>
	Tables2Traces	<b>0.42 ± 0.03</b>	<b>0.82 ± 0.03</b>	<b>0.38 ± 0.04</b>	0.08 ± 0.02	
<b>Medicine</b> ( <i>N</i> = 185)	Base	0.44 ± 0.03	0.84 ± 0.03	0.39 ± 0.04	0.12 ± 0.02	<b>+12.17% ↑</b>
	Tables2Traces	<b>0.50 ± 0.03</b>	<b>0.88 ± 0.02</b>	<b>0.45 ± 0.04</b>	<b>0.15 ± 0.03</b>	
<b>Microbiology</b> ( <i>N</i> = 74)	Base	0.45 ± 0.04	0.84 ± 0.04	<b>0.35 ± 0.06</b>	0.11 ± 0.04	<b>+7.55% ↑</b>
	Tables2Traces	<b>0.48 ± 0.04</b>	<b>0.91 ± 0.03</b>	<b>0.35 ± 0.06</b>	<b>0.15 ± 0.04</b>	
<b>Ophthalmology</b> ( <i>N</i> = 43)	Base	0.40 ± 0.05	<b>0.91 ± 0.04</b>	<b>0.30 ± 0.07</b>	0.14 ± 0.05	<b>+1.72% ↑</b>
	Tables2Traces	<b>0.41 ± 0.05</b>	0.88 ± 0.05	<b>0.30 ± 0.07</b>	<b>0.16 ± 0.06</b>	
<b>Orthopaedics</b> ( <i>N</i> = 15)	Base	<b>0.40 ± 0.08</b>	<b>0.87 ± 0.09</b>	<b>0.53 ± 0.13</b>	<b>0.00 ± 0.00</b>	<b>-15.00% ↓</b>
	Tables2Traces	0.34 ± 0.08	0.80 ± 0.11	0.27 ± 0.12	<b>0.00 ± 0.00</b>	
<b>Pathology</b> ( <i>N</i> = 259)	Base	0.51 ± 0.02	0.89 ± 0.02	0.44 ± 0.03	0.11 ± 0.02	<b>+5.82% ↑</b>
	Tables2Traces	<b>0.54 ± 0.02</b>	<b>0.92 ± 0.02</b>	<b>0.53 ± 0.03</b>	<b>0.16 ± 0.04</b>	
<b>Pediatrics</b> ( <i>N</i> = 133)	Base	0.44 ± 0.03	0.82 ± 0.03	<b>0.39 ± 0.04</b>	0.09 ± 0.02	<b>+6.52% ↑</b>
	Tables2Traces	<b>0.47 ± 0.03</b>	<b>0.86 ± 0.03</b>	0.38 ± 0.04	<b>0.12 ± 0.03</b>	
<b>Pharmacology</b> ( <i>N</i> = 179)	Base	0.52 ± 0.03	0.90 ± 0.02	0.46 ± 0.04	<b>0.17 ± 0.03</b>	<b>+8.30% ↑</b>
	Tables2Traces	<b>0.56 ± 0.02</b>	<b>0.93 ± 0.02</b>	<b>0.55 ± 0.04</b>	0.14 ± 0.03	
<b>Physiology</b> ( <i>N</i> = 133)	Base	0.46 ± 0.03	<b>0.86 ± 0.03</b>	<b>0.38 ± 0.04</b>	<b>0.16 ± 0.03</b>	<b>+2.30% ↑</b>
	Tables2Traces	<b>0.47 ± 0.03</b>	<b>0.86 ± 0.03</b>	<b>0.38 ± 0.04</b>	0.14 ± 0.03	
<b>Psychiatry</b> ( <i>N</i> = 10)	Base	0.41 ± 0.10	0.80 ± 0.13	0.30 ± 0.15	<b>0.00 ± 0.00</b>	<b>+31.71% ↑</b>
	Tables2Traces	<b>0.54 ± 0.09</b>	<b>0.90 ± 0.10</b>	<b>0.50 ± 0.17</b>	<b>0.00 ± 0.00</b>	
<b>Radiology</b> ( <i>N</i> = 57)	Base	<b>0.49 ± 0.04</b>	<b>0.93 ± 0.03</b>	<b>0.40 ± 0.07</b>	<b>0.05 ± 0.03</b>	<b>-8.54% ↓</b>
	Tables2Traces	0.45 ± 0.04	0.89 ± 0.04	0.39 ± 0.07	0.04 ± 0.02	
<b>Skin</b> ( <i>N</i> = 11)	Base	<b>0.37 ± 0.08</b>	<b>0.91 ± 0.09</b>	<b>0.27 ± 0.14</b>	0.00 ± 0.00	<b>-24.39% ↓</b>
	Tables2Traces	0.28 ± 0.10	0.73 ± 0.14	0.18 ± 0.12	<b>0.09 ± 0.09</b>	
<b>Social &amp; Preventive Medicine</b> ( <i>N</i> = 91)	Base	0.44 ± 0.04	0.81 ± 0.04	0.34 ± 0.05	<b>0.10 ± 0.03</b>	<b>+7.30% ↑</b>
	Tables2Traces	<b>0.47 ± 0.04</b>	<b>0.87 ± 0.04</b>	<b>0.43 ± 0.05</b>	0.09 ± 0.03	
<b>Surgery</b> ( <i>N</i> = 249)	Base	0.41 ± 0.02	<b>0.86 ± 0.02</b>	0.35 ± 0.03	<b>0.08 ± 0.02</b>	<b>+12.12% ↑</b>
	Tables2Traces	<b>0.46 ± 0.02</b>	<b>0.86 ± 0.02</b>	<b>0.40 ± 0.03</b>	<b>0.08 ± 0.02</b>	
<b>Unknown</b> ( <i>N</i> = 2)	Base	0.30 ± 0.30	<b>0.50 ± 0.50</b>	<b>0.50 ± 0.50</b>	<b>0.00 ± 0.00</b>	<b>+16.67% ↑</b>
	Tables2Traces	<b>0.35 ± 0.35</b>	<b>0.50 ± 0.50</b>	<b>0.50 ± 0.50</b>	<b>0.00 ± 0.00</b>	
<b>Overall</b> ( <i>N</i> = 2816)	Base	0.42 ± 0.01	0.85 ± 0.01	0.35 ± 0.01	0.09 ± 0.01	<b>+7.49% ↑</b>
	Tables2Traces	<b>0.45 ± 0.01</b>	<b>0.88 ± 0.01</b>	<b>0.38 ± 0.01</b>	<b>0.10 ± 0.01</b>	

## E MEDMCQA CATEGORY-LEVEL RESULTS

To further evaluate generalization, we analyze performance across medical specialties on the MedMCQA benchmark. As shown in Table 3, Tables2Traces improves performance across 17 of 21 categories, despite being fine-tuned exclusively on tabular data from a single clinical domain (cardiovascular). Notable gains appear in ENT (+16.56%), Social & Preventive Medicine (+16.67%), and Medicine (+12.71%), among others. While a few categories see drops (e.g., Skin, Orthopaedics), the overall gain is +7.49%. These results demonstrate that contrastive supervision derived from structured data can support generalization even to out-of-domain medical topics.

1404  
 1405 Table 4: Distribution of question types in MedQA and MedMCQA using LLM-based classification.  
 1406 Values are shown as raw counts and percentages of each dataset.

Benchmark	Patient-Specific	Abstract	Cardiovascular	Non-Cardiovascular
MedQA	1175 (92.3%)	98 (7.7%)	130 (10.2%)	1143 (89.8%)
MedMCQA	460 (16.3%)	2356 (83.7%)	226 (8.0%)	2590 (92.0%)

## F QUESTION TYPE DISTRIBUTIONS

1414 To better understand the nature of the questions in each benchmark, we classify them along two axes  
 1415 using an LLM-based approach: whether a question is *patient-specific* (referring to a concrete clinical  
 1416 case) or *abstract* (testing general medical knowledge), and whether it falls within the *cardiovascular*  
 1417 domain. As shown in Table 4, MedQA is overwhelmingly patient-specific (92.3%) and contains  
 1418 a small cardiovascular subset (10.2%). In contrast, MedMCQA is largely abstract (83.7%) and  
 1419 similarly skewed toward non-cardiovascular questions. This highlights the generalization challenge:  
 1420 our fine-tuned models, trained only on cardiovascular tabular data, are evaluated on questions that are  
 1421 mostly out-of-domain and structurally distinct.

1422  
 1423  
 1424  
 1425  
 1426  
 1427  
 1428  
 1429  
 1430  
 1431  
 1432  
 1433  
 1434  
 1435  
 1436  
 1437  
 1438  
 1439  
 1440  
 1441  
 1442  
 1443  
 1444  
 1445  
 1446  
 1447  
 1448  
 1449  
 1450  
 1451  
 1452  
 1453  
 1454  
 1455  
 1456  
 1457

1458 Table 5: Aloe fine-tuning with Tables2Traces supervision. Means and standard error estimates over  
 1459 10 inference runs.

1460

Model	Avg Accuracy
Aloe	$0.58 \pm 0.01$
Aloe + Tables2Traces	$0.56 \pm 0.01$

1464

## 1465 G ALOE FINE-TUNING RESULTS

1467 Aloe is a strong medical QA system trained on many curated datasets with synthetic chain-of-thought,  
 1468 guideline-based answers, and adversarial supervision. It is optimized for direct question answering  
 1469 rather than multi-step or counterfactual reasoning. We include Aloe as a point of contrast and test  
 1470 alignment: does reasoning supervision from Tables2Traces improve a QA-oriented model? We  
 1471 fine-tuned Aloe on the same Tables2Traces prompt-trace pairs and evaluated under identical test-time  
 1472 prompts and decoding settings as in the main experiments. Average accuracy decreases from 0.58  
 1473 to 0.56 with the same standard error, indicating no benefit from reasoning-based supervision. This  
 1474 supports the claim that Tables2Traces is orthogonal to expensive QA curation and that QA-specific  
 1475 training is misaligned with reasoning traces.

1476

1477

1478

1479

1480

1481

1482

1483

1484

1485

1486

1487

1488

1489

1490

1491

1492

1493

1494

1495

1496

1497

1498

1499

1500

1501

1502

1503

1504

1505

1506

1507

1508

1509

1510

1511




Figure 4: Accuracy on different question types in the MedQA benchmark across model sizes (7B and 8B) and fine-tuning methods. Tables2Traces yields large gains on cardiovascular and more modest gains patient-specific questions. On both cardiovascular and patient-specific questions both 7B and 8B models show consistent improvement. Minor gains are observed for non-cardiovascular questions except for the 8B Tables2Traces model. On abstract questions, all models underperform compared to the base model, except for the 8B Tables2Traces model. Values reflect relative improvement over the base model, with error bars denoting standard error across inference runs.

## H RESULTS FROM QWEN-7B MODELS

To assess whether the benefits of Tables2Traces generalize across model scales, we replicate our main experiments using Qwen models with 7 billion parameters. These models are evaluated on the same MedQA and MedMCQA benchmarks, using identical training procedures as the 8B counterparts. Unlike the 8B results, however, we observe that Tables2Traces provides less consistent improvements at this smaller scale—particularly on out-of-domain or abstract questions. In some cases, performance even degrades relative to the base model.

It is important to note that this comparison involves both a change in model size (8B  $\rightarrow$  7B) and architecture (LLaMA  $\rightarrow$  Qwen), so the effects cannot be attributed to scaling alone. These results suggest that both model capacity and architecture may influence the effectiveness of structured, trace-based supervision.

### H.1 MEDQA

Figure 4 shows performance on the MedQA benchmark, stratified by question type and model size (7B vs. 8B). Tables2Traces yields substantial improvements on cardiovascular questions (up to +17.2%) and consistent gains on patient-specific questions, especially at the 8B scale. This suggests that structured reasoning supervision is particularly effective for case-based clinical reasoning tasks.

Performance on non-cardiovascular questions improves only modestly, and the Tables2Traces (simple) variant offers little benefit over the base model. For abstract questions, all 7B models underperform, and only Tables2Traces 8B retains accuracy. These results highlight the importance of contrastive, trace-based supervision for enabling models to generalize beyond narrowly defined training inputs.




Figure 5: Accuracy on different question types in the MedMCQA benchmark across model sizes (7B and 8B) and fine-tuning methods. At 8B, Tables2Traces improves performance on all question types, including abstract and non-cardiovascular questions. In contrast, 7B models show inconsistent or negative gains, particularly for out-of-domain categories. These results suggest that contrastive supervision derived from tabular data is more effective at scale, and can generalize beyond the source domain when model capacity is sufficient. Values show relative accuracy improvements over the base model, with error bars denoting standard error across inference runs.

## H.2 MEDMCQA

Figure 5 shows model performance on the MedMCQA benchmark, stratified by question type and model size. Tables2Traces yields gains at the 8B scale, improving accuracy on cardiovascular, abstract, and non-cardiovascular questions. Relative gains reach +10.6% on cardiovascular questions and +7.6% on abstract ones.

At the 7B scale, results are more mixed. Both Tables2Traces and Tables2Traces (simple) underperform the base model on most question types, suggesting that smaller models struggle to benefit from structured supervision alone. These findings reinforce the idea that contrastive, trace-based supervision is especially valuable when paired with sufficient model capacity.

1620 Table 6: Per-category evaluation metrics on MedQA for Tables2Traces (simple) and Tables2Traces  
 1621 (8B). % Change refers to change in performance relative to the Base model.

Category	Model Type	Avg Accuracy	Best-of-n	Majority Vote	Worst-of-n	% Change
<b>Cardiovascular</b> ( <i>N</i> = 130)	Tables2Traces (simple)	0.46 ± 0.03	0.86 ± 0.03	<b>0.42 ± 0.04</b>	<b>0.06 ± 0.02</b>	+13.19% ↑
	Tables2Traces	<b>0.47 ± 0.03</b>	<b>0.91 ± 0.03</b>	<b>0.42 ± 0.04</b>	<b>0.06 ± 0.02</b>	+17.21% ↑
<b>Dermatologic</b> ( <i>N</i> = 17)	Tables2Traces (simple)	<b>0.71 ± 0.09</b>	<b>0.94 ± 0.06</b>	<b>0.76 ± 0.11</b>	<b>0.29 ± 0.11</b>	+18.81% ↑
	Tables2Traces	0.60 ± 0.08	0.88 ± 0.08	0.59 ± 0.12	0.12 ± 0.08	+0.99% ↑
<b>Endocrine/Metabolic</b> ( <i>N</i> = 179)	Tables2Traces (simple)	<b>0.52 ± 0.02</b>	<b>0.95 ± 0.02</b>	<b>0.47 ± 0.04</b>	<b>0.10 ± 0.02</b>	6.09% ↑
	Tables2Traces	0.51 ± 0.02	0.91 ± 0.02	0.46 ± 0.04	<b>0.10 ± 0.02</b>	4.71% ↑
<b>Gastrointestinal</b> ( <i>N</i> = 86)	Tables2Traces (simple)	0.44 ± 0.04	0.88 ± 0.04	0.38 ± 0.05	<b>0.09 ± 0.03</b>	-5.72% ↓
	Tables2Traces	<b>0.50 ± 0.04</b>	<b>0.91 ± 0.03</b>	<b>0.47 ± 0.05</b>	0.08 ± 0.03	+6.72% ↑
<b>Hematologic</b> ( <i>N</i> = 68)	Tables2Traces (simple)	0.38 ± 0.03	0.90 ± 0.04	0.25 ± 0.05	0.03 ± 0.02	-6.93% ↓
	Tables2Traces	<b>0.48 ± 0.04</b>	<b>0.91 ± 0.04</b>	<b>0.43 ± 0.06</b>	<b>0.07 ± 0.03</b>	+18.98% ↑
<b>Immunologic</b> ( <i>N</i> = 81)	Tables2Traces (simple)	0.50 ± 0.04	0.93 ± 0.03	0.44 ± 0.06	0.09 ± 0.03	-2.67% ↓
	Tables2Traces	<b>0.54 ± 0.04</b>	<b>0.94 ± 0.03</b>	<b>0.46 ± 0.06</b>	<b>0.17 ± 0.04</b>	+6.80% ↑
<b>Infectious</b> ( <i>N</i> = 176)	Tables2Traces (simple)	0.46 ± 0.02	0.92 ± 0.02	0.40 ± 0.04	0.06 ± 0.02	-3.44% ↓
	Tables2Traces	<b>0.53 ± 0.02</b>	<b>0.94 ± 0.02</b>	<b>0.45 ± 0.04</b>	<b>0.11 ± 0.02</b>	+9.73% ↑
<b>Musculoskeletal</b> ( <i>N</i> = 45)	Tables2Traces (simple)	0.48 ± 0.05	0.89 ± 0.05	<b>0.42 ± 0.07</b>	0.04 ± 0.03	-2.71% ↓
	Tables2Traces	<b>0.51 ± 0.04</b>	<b>0.96 ± 0.03</b>	0.40 ± 0.07	<b>0.07 ± 0.04</b>	+4.07% ↑
<b>Neurological</b> ( <i>N</i> = 77)	Tables2Traces (simple)	0.47 ± 0.04	0.86 ± 0.04	0.42 ± 0.06	<b>0.09 ± 0.03</b>	+6.89% ↑
	Tables2Traces	<b>0.50 ± 0.04</b>	<b>0.90 ± 0.04</b>	<b>0.43 ± 0.06</b>	0.05 ± 0.02	+15.15% ↑
<b>Obstetrics/Gynecology</b> ( <i>N</i> = 70)	Tables2Traces (simple)	0.46 ± 0.04	0.93 ± 0.03	<b>0.43 ± 0.06</b>	<b>0.07 ± 0.03</b>	+0.93% ↑
	Tables2Traces	<b>0.47 ± 0.03</b>	<b>0.94 ± 0.03</b>	0.40 ± 0.06	0.03 ± 0.02	+2.80% ↑
<b>Oncology</b> ( <i>N</i> = 72)	Tables2Traces (simple)	0.50 ± 0.04	0.86 ± 0.04	0.47 ± 0.06	<b>0.15 ± 0.04</b>	-4.76% ↓
	Tables2Traces	<b>0.56 ± 0.04</b>	<b>0.93 ± 0.03</b>	<b>0.53 ± 0.06</b>	0.14 ± 0.04	+5.82% ↑
<b>Other</b> ( <i>N</i> = 31)	Tables2Traces (simple)	0.45 ± 0.06	0.84 ± 0.07	<b>0.45 ± 0.09</b>	0.10 ± 0.05	-15.24% ↓
	Tables2Traces	<b>0.50 ± 0.07</b>	<b>0.87 ± 0.06</b>	0.42 ± 0.09	<b>0.19 ± 0.07</b>	-4.88% ↓
<b>Pediatric</b> ( <i>N</i> = 13)	Tables2Traces (simple)	0.32 ± 0.07	0.92 ± 0.08	0.23 ± 0.12	<b>0.00 ± 0.00</b>	-19.61% ↓
	Tables2Traces	<b>0.39 ± 0.05</b>	<b>1.00 ± 0.00</b>	<b>0.31 ± 0.13</b>	<b>0.00 ± 0.00</b>	-1.96% ↓
<b>Psychiatric</b> ( <i>N</i> = 52)	Tables2Traces (simple)	0.60 ± 0.05	<b>0.94 ± 0.03</b>	0.58 ± 0.07	<b>0.21 ± 0.06</b>	+2.30% ↑
	Tables2Traces	<b>0.62 ± 0.05</b>	0.90 ± 0.04	<b>0.61 ± 0.07</b>	<b>0.21 ± 0.06</b>	+5.57% ↑
<b>Renal/Genitourinary</b> ( <i>N</i> = 54)	Tables2Traces (simple)	0.42 ± 0.04	0.93 ± 0.04	0.35 ± 0.07	0.06 ± 0.03	+15.08% ↑
	Tables2Traces	<b>0.48 ± 0.04</b>	<b>0.96 ± 0.03</b>	<b>0.41 ± 0.07</b>	<b>0.09 ± 0.04</b>	+29.65% ↑
<b>Respiratory</b> ( <i>N</i> = 54)	Tables2Traces (simple)	0.49 ± 0.04	0.93 ± 0.04	0.44 ± 0.07	<b>0.11 ± 0.04</b>	+0.76% ↑
	Tables2Traces	<b>0.50 ± 0.04</b>	<b>0.94 ± 0.03</b>	<b>0.46 ± 0.07</b>	<b>0.11 ± 0.04</b>	+2.28% ↑
<b>Toxicology</b> ( <i>N</i> = 68)	Tables2Traces (simple)	0.41 ± 0.04	<b>0.93 ± 0.03</b>	0.35 ± 0.06	0.03 ± 0.02	-6.10% ↓
	Tables2Traces	<b>0.52 ± 0.04</b>	0.91 ± 0.04	<b>0.47 ± 0.06</b>	<b>0.09 ± 0.04</b>	+20.68% ↑
<b>Overall</b> ( <i>N</i> = 1273)	Tables2Traces (simple)	0.47 ± 0.01	0.91 ± 0.01	0.42 ± 0.01	0.08 ± 0.01	+0.82% ↑
	Tables2Traces	<b>0.51 ± 0.01</b>	<b>0.93 ± 0.01</b>	<b>0.46 ± 0.01</b>	<b>0.10 ± 0.01</b>	+9.19% ↑

## I PER-CATEGORY RESULTS FROM TABLES2TRACES (SIMPLE)


Table 6 reports category-level results for both Tables2Traces and its ablated variant, Tables2Traces (simple), on the MedQA benchmark. Across most categories, the full method consistently outperforms the simple variant, highlighting the added value of contrastive and counterfactual reasoning supervision. However, the simple variant still delivers strong gains over the base model in several categories, including Cardiovascular (+13.19%), Renal/Genitourinary (+15.08%) and Neurological (+6.89%). This table complements the main figures by providing a more granular view of how each model variant performs across medical specialties.

Table 7: Per-category evaluation metrics on MedMCQA for Base and Aloe (8B).

Category	Model Type	Avg Accuracy	Best-of-n	Majority Vote	Worst-of-n	% Change
<b>Anaesthesia</b> ( <i>N</i> = 24)	Base	0.36 ± 0.07	<b>0.88 ± 0.07</b>	0.29 ± 0.09	<b>0.08 ± 0.06</b>	
	Aloe	<b>0.46 ± 0.07</b>	0.79 ± 0.08	<b>0.46 ± 0.10</b>	<b>0.08 ± 0.06</b>	<b>+26.44%↑</b>
<b>Anatomy</b> ( <i>N</i> = 147)	Base	0.36 ± 0.02	<b>0.86 ± 0.03</b>	0.26 ± 0.04	0.02 ± 0.01	
	Aloe	<b>0.49 ± 0.03</b>	<b>0.86 ± 0.03</b>	<b>0.42 ± 0.04</b>	<b>0.14 ± 0.03</b>	<b>+37.05%↑</b>
<b>Biochemistry</b> ( <i>N</i> = 122)	Base	0.57 ± 0.03	0.90 ± 0.03	0.58 ± 0.04	0.11 ± 0.03	
	Aloe	<b>0.69 ± 0.03</b>	<b>0.93 ± 0.02</b>	<b>0.66 ± 0.04</b>	<b>0.38 ± 0.04</b>	<b>+21.59%↑</b>
<b>Dental</b> ( <i>N</i> = 845)	Base	0.35 ± 0.01	0.82 ± 0.01	0.26 ± 0.02	0.05 ± 0.01	
	Aloe	<b>0.41 ± 0.01</b>	<b>0.84 ± 0.01</b>	<b>0.34 ± 0.02</b>	<b>0.11 ± 0.01</b>	<b>+15.61%↑</b>
<b>ENT</b> ( <i>N</i> = 39)	Base	0.39 ± 0.05	<b>0.92 ± 0.04</b>	0.26 ± 0.07	0.08 ± 0.04	
	Aloe	<b>0.55 ± 0.06</b>	0.90 ± 0.05	<b>0.51 ± 0.08</b>	<b>0.23 ± 0.07</b>	<b>+41.06%↑</b>
<b>Forensic Medicine</b> ( <i>N</i> = 44)	Base	0.41 ± 0.05	<b>0.89 ± 0.05</b>	0.32 ± 0.07	0.09 ± 0.04	
	Aloe	<b>0.50 ± 0.05</b>	<b>0.89 ± 0.05</b>	<b>0.43 ± 0.08</b>	<b>0.20 ± 0.06</b>	<b>+20.88%↑</b>
<b>Gynaecology &amp; Obstetrics</b> ( <i>N</i> = 154)	Base	0.40 ± 0.03	0.81 ± 0.03	0.32 ± 0.04	0.09 ± 0.02	
	Aloe	<b>0.53 ± 0.03</b>	<b>0.89 ± 0.03</b>	<b>0.46 ± 0.04</b>	<b>0.21 ± 0.03</b>	<b>+30.43%↑</b>
<b>Medicine</b> ( <i>N</i> = 185)	Base	0.44 ± 0.03	0.84 ± 0.03	0.39 ± 0.04	0.12 ± 0.02	
	Aloe	<b>0.58 ± 0.03</b>	<b>0.90 ± 0.02</b>	<b>0.54 ± 0.04</b>	<b>0.26 ± 0.03</b>	<b>+29.93%↑</b>
<b>Microbiology</b> ( <i>N</i> = 74)	Base	0.45 ± 0.04	0.84 ± 0.04	0.35 ± 0.06	0.11 ± 0.04	
	Aloe	<b>0.58 ± 0.04</b>	<b>0.89 ± 0.04</b>	<b>0.55 ± 0.06</b>	<b>0.24 ± 0.05</b>	<b>+29.31%↑</b>
<b>Ophthalmology</b> ( <i>N</i> = 43)	Base	0.40 ± 0.05	0.91 ± 0.04	0.30 ± 0.07	0.14 ± 0.05	
	Aloe	<b>0.54 ± 0.06</b>	<b>0.93 ± 0.04</b>	<b>0.49 ± 0.08</b>	<b>0.23 ± 0.07</b>	<b>+34.48%↑</b>
<b>Orthopaedics</b> ( <i>N</i> = 15)	Base	0.40 ± 0.08	0.87 ± 0.09	0.53 ± 0.13	0.00 ± 0.00	
	Aloe	<b>0.59 ± 0.08</b>	<b>0.93 ± 0.07</b>	<b>0.60 ± 0.13</b>	<b>0.13 ± 0.09</b>	<b>+46.67%↑</b>
<b>Pathology</b> ( <i>N</i> = 259)	Base	0.51 ± 0.02	0.89 ± 0.02	0.44 ± 0.03	0.11 ± 0.02	
	Aloe	<b>0.65 ± 0.02</b>	<b>0.91 ± 0.02</b>	<b>0.64 ± 0.03</b>	<b>0.32 ± 0.03</b>	<b>+27.73%↑</b>
<b>Pediatrics</b> ( <i>N</i> = 133)	Base	0.44 ± 0.03	0.82 ± 0.03	0.39 ± 0.04	0.09 ± 0.02	
	Aloe	<b>0.57 ± 0.03</b>	<b>0.90 ± 0.03</b>	<b>0.51 ± 0.04</b>	<b>0.19 ± 0.03</b>	<b>+31.05%↑</b>
<b>Pharmacology</b> ( <i>N</i> = 179)	Base	0.52 ± 0.03	0.90 ± 0.02	0.46 ± 0.04	0.17 ± 0.03	
	Aloe	<b>0.72 ± 0.03</b>	<b>0.93 ± 0.02</b>	<b>0.69 ± 0.03</b>	<b>0.43 ± 0.04</b>	<b>+38.04%↑</b>
<b>Physiology</b> ( <i>N</i> = 133)	Base	0.46 ± 0.03	0.86 ± 0.03	0.38 ± 0.04	0.16 ± 0.03	
	Aloe	<b>0.60 ± 0.03</b>	<b>0.89 ± 0.03</b>	<b>0.58 ± 0.04</b>	<b>0.29 ± 0.04</b>	<b>+31.2%↑</b>
<b>Psychiatry</b> ( <i>N</i> = 10)	Base	0.41 ± 0.10	0.80 ± 0.13	0.30 ± 0.15	0.00 ± 0.00	
	Aloe	<b>0.60 ± 0.13</b>	<b>0.90 ± 0.10</b>	<b>0.60 ± 0.16</b>	<b>0.30 ± 0.15</b>	<b>+46.34%↑</b>
<b>Radiology</b> ( <i>N</i> = 57)	Base	0.49 ± 0.04	<b>0.93 ± 0.03</b>	0.40 ± 0.07	0.05 ± 0.03	
	Aloe	<b>0.51 ± 0.05</b>	0.89 ± 0.04	<b>0.44 ± 0.07</b>	<b>0.14 ± 0.05</b>	<b>+2.85%↑</b>
<b>Skin</b> ( <i>N</i> = 11)	Base	0.37 ± 0.08	<b>0.91 ± 0.09</b>	0.27 ± 0.14	0.00 ± 0.00	
	Aloe	<b>0.47 ± 0.12</b>	0.73 ± 0.14	<b>0.36 ± 0.15</b>	<b>0.18 ± 0.12</b>	<b>+26.83%↑</b>
<b>Social &amp; Preventive Medicine</b> ( <i>N</i> = 91)	Base	0.44 ± 0.04	0.81 ± 0.04	0.34 ± 0.05	0.10 ± 0.03	
	Aloe	<b>0.52 ± 0.04</b>	<b>0.88 ± 0.03</b>	<b>0.47 ± 0.05</b>	<b>0.20 ± 0.04</b>	<b>+19.14%↑</b>
<b>Surgery</b> ( <i>N</i> = 249)	Base	0.41 ± 0.02	<b>0.86 ± 0.02</b>	0.35 ± 0.03	0.08 ± 0.02	
	Aloe	<b>0.51 ± 0.02</b>	<b>0.86 ± 0.02</b>	<b>0.47 ± 0.03</b>	<b>0.17 ± 0.02</b>	<b>+24.24%↑</b>
<b>Unknown</b> ( <i>N</i> = 2)	Base	<b>0.30 ± 0.30</b>	<b>0.50 ± 0.50</b>	<b>0.50 ± 0.50</b>	<b>0.00 ± 0.00</b>	
	Aloe	0.20 ± 0.20	<b>0.50 ± 0.50</b>	0.00 ± 0.00	<b>0.00 ± 0.00</b>	<b>-33.33%↓</b>
<b>Overall</b> ( <i>N</i> = 2816)	Base	0.42 ± 0.01	0.85 ± 0.01	0.35 ± 0.01	0.09 ± 0.01	
	Aloe	<b>0.53 ± 0.01</b>	<b>0.88 ± 0.01</b>	<b>0.48 ± 0.01</b>	<b>0.21 ± 0.01</b>	<b>+25.31%↑</b>

## J PER-CATEGORY RESULTS FROM ALOE

For completeness, we report a category-level breakdown of Aloe’s performance on the MedMCQA benchmark in Table 7. Aloe achieves consistent improvements over the base model across nearly all medical specialties, with an overall relative gain of +25.31%. Gains are especially large in domains such as Psychiatry (+46.34%), Orthopaedics (+46.67%), and Pharmacology (+38.04%). Only one category (Unknown) shows a performance regression, but it notably only contains two questions. These results align with Aloe’s strong overall performance and provide additional insight into which specialties benefit most from its QA-style supervision. We note that Aloe is an upper-bound baseline and that our work is best viewed as a complementary approach rather than a competing one.



1763 Figure 6: UMAP visualization of MedMCQA test questions, comparing model per-  
1764 formance to the **Base** model. Each point represents a question, embedded using  
1765 text-embedding-3-large (OpenAI, 2023), and annotated by medical category using  
1766 distinct marker shapes and colors. The background heatmap reflects smoothed relative accuracy: red  
1767 indicates improved performance, blue indicates degradation. **(a)** Tables2Traces shows consistent  
1768 gains across diverse medical categories. **(b)** Tables2Traces (simple) displays more variable patterns,  
1769 with several regions showing decreased performance. Cluster labels indicate category centroids.

## K UMAP VISUALIZATION OF MEDMCQA

1775 Figure 6 shows a UMAP projection of MedMCQA test questions, colored by medical category  
1776 and overlaid with performance changes relative to the base model. As in MedQA, Tables2Traces  
1777 (Figure 6a) shows widespread gains across the space. Notable improvements appear in regions  
1778 corresponding to Anatomy, Dental, and Pathology.

1779 In contrast, Tables2Traces (simple) (Figure 6b) demonstrates a more fragmented pattern. While  
1780 some clusters benefit (e.g., Dental, Anatomy), others experience performance drops, particularly  
1781 in Biochemistry and Pharmacology. These results further support the conclusion that structured  
1782 contrastive supervision is critical for consistent generalization beyond the source domain.

1782 Table 8: Per-category evaluation metrics on the MedQA benchmark for Base and QA-Finetuning  
1783 (8B).

Category	Model Type	Avg Accuracy	Best-of-n	Majority Vote	Worst-of-n	% Change
<b>Cardiovascular</b> ( <i>N</i> = 130)	Base	<b>0.40 ± 0.03</b>	0.86 ± 0.03	<b>0.31 ± 0.04</b>	<b>0.06 ± 0.02</b>	<span style="color: red;">-3.63% ↓</span>
	QA-Finetuning	0.39 ± 0.02	<b>0.89 ± 0.03</b>	0.30 ± 0.04	0.03 ± 0.02	
<b>Dermatologic</b> ( <i>N</i> = 17)	Base	<b>0.59 ± 0.08</b>	<b>0.94 ± 0.06</b>	<b>0.53 ± 0.12</b>	<b>0.06 ± 0.06</b>	<span style="color: red;">-9.9% ↓</span>
	QA-Finetuning	0.54 ± 0.07	<b>0.94 ± 0.06</b>	<b>0.53 ± 0.12</b>	<b>0.06 ± 0.06</b>	
<b>Endocrine/Metabolic</b> ( <i>N</i> = 179)	Base	<b>0.49 ± 0.03</b>	0.89 ± 0.02	<b>0.45 ± 0.04</b>	<b>0.13 ± 0.03</b>	<span style="color: red;">-6.55% ↓</span>
	QA-Finetuning	0.45 ± 0.02	<b>0.91 ± 0.02</b>	0.40 ± 0.04	0.06 ± 0.02	
<b>Gastrointestinal</b> ( <i>N</i> = 86)	Base	<b>0.47 ± 0.04</b>	0.87 ± 0.04	<b>0.40 ± 0.05</b>	<b>0.12 ± 0.04</b>	<span style="color: red;">-3.73% ↓</span>
	QA-Finetuning	0.45 ± 0.03	<b>0.88 ± 0.03</b>	0.37 ± 0.05	0.07 ± 0.03	
<b>Hematologic</b> ( <i>N</i> = 68)	Base	0.40 ± 0.04	0.84 ± 0.04	0.34 ± 0.06	<b>0.04 ± 0.03</b>	<span style="color: green;">+5.11% ↑</span>
	QA-Finetuning	<b>0.42 ± 0.04</b>	<b>0.87 ± 0.04</b>	<b>0.37 ± 0.06</b>	<b>0.04 ± 0.03</b>	
<b>Immunologic</b> ( <i>N</i> = 81)	Base	<b>0.51 ± 0.04</b>	0.85 ± 0.04	<b>0.47 ± 0.06</b>	<b>0.22 ± 0.05</b>	<span style="color: red;">-2.43% ↓</span>
	QA-Finetuning	0.50 ± 0.03	<b>0.94 ± 0.03</b>	0.43 ± 0.06	0.10 ± 0.03	
<b>Infectious</b> ( <i>N</i> = 176)	Base	<b>0.48 ± 0.03</b>	<b>0.92 ± 0.02</b>	<b>0.41 ± 0.04</b>	<b>0.11 ± 0.02</b>	<span style="color: red;">-4.98% ↓</span>
	QA-Finetuning	0.46 ± 0.02	0.90 ± 0.02	0.37 ± 0.04	0.07 ± 0.02	
<b>Musculoskeletal</b> ( <i>N</i> = 45)	Base	<b>0.49 ± 0.05</b>	0.89 ± 0.05	<b>0.49 ± 0.07</b>	<b>0.04 ± 0.03</b>	<span style="color: red;">-8.14% ↓</span>
	QA-Finetuning	0.45 ± 0.04	<b>0.98 ± 0.02</b>	0.33 ± 0.07	0.02 ± 0.02	
<b>Neurological</b> ( <i>N</i> = 77)	Base	0.47 ± 0.04	0.86 ± 0.04	0.42 ± 0.06	<b>0.09 ± 0.03</b>	<span style="color: green;">+8.26% ↑</span>
	QA-Finetuning	<b>0.51 ± 0.03</b>	<b>0.96 ± 0.02</b>	<b>0.44 ± 0.06</b>	0.06 ± 0.03	
<b>Obstetrics/Gynecology</b> ( <i>N</i> = 70)	Base	<b>0.46 ± 0.04</b>	0.90 ± 0.04	<b>0.39 ± 0.06</b>	<b>0.09 ± 0.03</b>	<span style="color: red;">-1.86% ↓</span>
	QA-Finetuning	0.45 ± 0.03	<b>0.91 ± 0.03</b>	<b>0.39 ± 0.06</b>	0.03 ± 0.02	
<b>Oncology</b> ( <i>N</i> = 72)	Base	<b>0.53 ± 0.04</b>	<b>0.92 ± 0.03</b>	<b>0.47 ± 0.06</b>	<b>0.11 ± 0.04</b>	<span style="color: red;">-13.23% ↓</span>
	QA-Finetuning	0.46 ± 0.04	0.90 ± 0.04	0.44 ± 0.06	0.06 ± 0.03	
<b>Other</b> ( <i>N</i> = 31)	Base	<b>0.53 ± 0.07</b>	0.77 ± 0.08	<b>0.45 ± 0.09</b>	<b>0.23 ± 0.08</b>	<span style="color: red;">-8.54% ↓</span>
	QA-Finetuning	0.48 ± 0.06	<b>0.90 ± 0.05</b>	<b>0.45 ± 0.09</b>	0.16 ± 0.07	
<b>Pediatric</b> ( <i>N</i> = 13)	Base	0.39 ± 0.09	0.77 ± 0.12	<b>0.39 ± 0.14</b>	0.00 ± 0.00	<span style="color: green;">+9.8% ↑</span>
	QA-Finetuning	<b>0.43 ± 0.09</b>	<b>0.85 ± 0.10</b>	0.38 ± 0.14	<b>0.08 ± 0.08</b>	
<b>Psychiatric</b> ( <i>N</i> = 52)	Base	<b>0.59 ± 0.05</b>	<b>0.94 ± 0.03</b>	<b>0.54 ± 0.07</b>	<b>0.23 ± 0.06</b>	<span style="color: red;">-8.85% ↓</span>
	QA-Finetuning	0.53 ± 0.04	0.88 ± 0.04	0.50 ± 0.07	0.13 ± 0.05	
<b>Renal/Genitourinary</b> ( <i>N</i> = 54)	Base	0.37 ± 0.04	0.85 ± 0.05	0.26 ± 0.06	0.04 ± 0.03	<span style="color: green;">+13.57% ↑</span>
	QA-Finetuning	<b>0.42 ± 0.04</b>	<b>0.93 ± 0.04</b>	<b>0.30 ± 0.06</b>	<b>0.06 ± 0.03</b>	
<b>Respiratory</b> ( <i>N</i> = 54)	Base	0.49 ± 0.04	<b>0.91 ± 0.04</b>	0.43 ± 0.07	<b>0.09 ± 0.04</b>	<span style="color: green;">+2.66% ↑</span>
	QA-Finetuning	<b>0.50 ± 0.04</b>	<b>0.91 ± 0.04</b>	<b>0.48 ± 0.07</b>	<b>0.09 ± 0.04</b>	
<b>Toxicology</b> ( <i>N</i> = 68)	Base	<b>0.43 ± 0.04</b>	0.79 ± 0.05	<b>0.41 ± 0.06</b>	<b>0.06 ± 0.03</b>	<span style="color: red;">-1.69% ↓</span>
	QA-Finetuning	<b>0.43 ± 0.03</b>	<b>0.93 ± 0.03</b>	0.29 ± 0.06	0.03 ± 0.02	
<b>Overall</b> ( <i>N</i> = 1273)	Base	<b>0.47 ± 0.01</b>	0.88 ± 0.01	<b>0.41 ± 0.01</b>	<b>0.11 ± 0.01</b>	<span style="color: red;">-3.17% ↓</span>
	QA-Finetuning	0.46 ± 0.01	<b>0.91 ± 0.01</b>	0.39 ± 0.01	0.06 ± 0.01	

## L QA-ONLY ABLATION RESULTS

To assess whether standard QA-format supervision could account for the performance improvements observed in our full method, we conduct an ablation where the model is fine-tuned exclusively on the 10k QA-format examples used in the mixed setup. Importantly, these 10K QA-format examples do not overlap with the questions used for evaluation. Results are shown in Table 8 (MedQA) and Table 9 (MedMCQA).

On MedQA, the QA-only model performs comparably or slightly worse than the base model (0.46 vs. 0.47 average accuracy), with inconsistent effects across clinical categories. On MedMCQA, the QA-only model performs worse than the base model overall (0.40 vs. 0.42 average accuracy) and shows negative or negligible gains across most categories. These results indicate that the QA examples alone do not explain the improvements observed in our main models.

1836  
1837

Table 9: Per-category evaluation metrics on MedMCQA for Base and QA-finetuning (8B).

1838  
1839  
1840  
1841  
1842  
1843  
1844  
1845  
1846  
1847  
1848  
1849  
1850  
1851  
1852  
1853  
1854  
1855  
1856  
1857  
1858  
1859  
1860  
1861  
1862  
1863  
1864  
1865  
1866  
1867  
1868  
1869  
1870  
1871

Category	Model Type	Avg Accuracy	Best-of-n	Majority Vote	Worst-of-n	% Change
<b>Anaesthesia</b> ( <i>N</i> = 24)	Base	<b>0.36 ± 0.07</b>	<b>0.88 ± 0.07</b>	<b>0.29 ± 0.09</b>	<b>0.08 ± 0.06</b>	
	QA-Finetuning	0.25 ± 0.04	0.83 ± 0.08	0.04 ± 0.04	0.00 ± 0.00	<b>-29.89%↓</b>
<b>Anatomy</b> ( <i>N</i> = 147)	Base	<b>0.36 ± 0.02</b>	0.86 ± 0.03	<b>0.26 ± 0.04</b>	<b>0.02 ± 0.01</b>	
	QA-Finetuning	0.33 ± 0.02	<b>0.89 ± 0.03</b>	0.23 ± 0.03	0.01 ± 0.01	<b>-8.70%↓</b>
<b>Biochemistry</b> ( <i>N</i> = 122)	Base	<b>0.57 ± 0.03</b>	<b>0.90 ± 0.03</b>	<b>0.58 ± 0.04</b>	0.11 ± 0.03	
	QA-Finetuning	0.51 ± 0.03	<b>0.90 ± 0.03</b>	0.49 ± 0.05	<b>0.12 ± 0.03</b>	<b>-9.57%↓</b>
<b>Dental</b> ( <i>N</i> = 845)	Base	<b>0.35 ± 0.01</b>	0.82 ± 0.01	<b>0.26 ± 0.02</b>	<b>0.05 ± 0.01</b>	
	QA-Finetuning	0.34 ± 0.01	<b>0.86 ± 0.01</b>	0.23 ± 0.01	0.03 ± 0.01	<b>-4.90%↓</b>
<b>ENT</b> ( <i>N</i> = 39)	Base	0.39 ± 0.05	<b>0.92 ± 0.04</b>	0.26 ± 0.07	<b>0.08 ± 0.04</b>	
	QA-Finetuning	<b>0.42 ± 0.05</b>	0.90 ± 0.05	<b>0.28 ± 0.07</b>	<b>0.08 ± 0.04</b>	<b>+7.28%↑</b>
<b>Forensic Medicine</b> ( <i>N</i> = 44)	Base	<b>0.41 ± 0.05</b>	<b>0.89 ± 0.05</b>	<b>0.32 ± 0.07</b>	<b>0.09 ± 0.04</b>	
	QA-Finetuning	0.36 ± 0.05	0.86 ± 0.05	0.25 ± 0.07	0.07 ± 0.04	<b>-12.64%↓</b>
<b>Gynaecology &amp; Obstetrics</b> ( <i>N</i> = 154)	Base	<b>0.40 ± 0.03</b>	0.81 ± 0.03	<b>0.32 ± 0.04</b>	<b>0.09 ± 0.02</b>	
	QA-Finetuning	0.37 ± 0.02	<b>0.86 ± 0.03</b>	0.31 ± 0.04	0.03 ± 0.01	<b>-7.41%↓</b>
<b>Medicine</b> ( <i>N</i> = 185)	Base	<b>0.44 ± 0.03</b>	0.84 ± 0.03	<b>0.39 ± 0.04</b>	<b>0.12 ± 0.02</b>	
	QA-Finetuning	<b>0.44 ± 0.02</b>	<b>0.87 ± 0.02</b>	0.36 ± 0.04	0.09 ± 0.02	<b>-0.73%↓</b>
<b>Microbiology</b> ( <i>N</i> = 74)	Base	<b>0.45 ± 0.04</b>	0.84 ± 0.04	0.35 ± 0.06	<b>0.11 ± 0.04</b>	
	QA-Finetuning	0.42 ± 0.04	<b>0.86 ± 0.04</b>	<b>0.36 ± 0.06</b>	0.04 ± 0.02	<b>-5.74%↓</b>
<b>Ophthalmology</b> ( <i>N</i> = 43)	Base	0.40 ± 0.05	0.91 ± 0.04	0.30 ± 0.07	<b>0.14 ± 0.05</b>	
	QA-Finetuning	<b>0.41 ± 0.05</b>	<b>0.93 ± 0.04</b>	<b>0.33 ± 0.07</b>	0.05 ± 0.03	<b>+0.57%↑</b>
<b>Orthopaedics</b> ( <i>N</i> = 15)	Base	<b>0.40 ± 0.08</b>	<b>0.87 ± 0.09</b>	<b>0.53 ± 0.13</b>	0.00 ± 0.00	
	QA-Finetuning	0.38 ± 0.07	<b>0.87 ± 0.09</b>	0.27 ± 0.12	<b>0.07 ± 0.07</b>	<b>-5.00%↓</b>
<b>Pathology</b> ( <i>N</i> = 259)	Base	<b>0.51 ± 0.02</b>	0.89 ± 0.02	<b>0.44 ± 0.03</b>	<b>0.11 ± 0.02</b>	
	QA-Finetuning	0.45 ± 0.02	<b>0.90 ± 0.02</b>	0.37 ± 0.03	0.06 ± 0.01	<b>-10.92%↓</b>
<b>Pediatrics</b> ( <i>N</i> = 133)	Base	<b>0.44 ± 0.03</b>	0.82 ± 0.03	<b>0.39 ± 0.04</b>	<b>0.09 ± 0.02</b>	
	QA-Finetuning	<b>0.44 ± 0.03</b>	<b>0.87 ± 0.03</b>	0.37 ± 0.04	0.05 ± 0.02	<b>+0.86%↑</b>
<b>Pharmacology</b> ( <i>N</i> = 179)	Base	<b>0.52 ± 0.03</b>	<b>0.90 ± 0.02</b>	<b>0.46 ± 0.04</b>	<b>0.17 ± 0.03</b>	
	QA-Finetuning	0.50 ± 0.02	<b>0.90 ± 0.02</b>	0.44 ± 0.04	0.12 ± 0.02	<b>-3.13%↓</b>
<b>Physiology</b> ( <i>N</i> = 133)	Base	<b>0.46 ± 0.03</b>	0.86 ± 0.03	<b>0.38 ± 0.04</b>	<b>0.16 ± 0.03</b>	
	QA-Finetuning	0.45 ± 0.03	<b>0.87 ± 0.03</b>	<b>0.38 ± 0.04</b>	0.12 ± 0.03	<b>-2.79%↓</b>
<b>Psychiatry</b> ( <i>N</i> = 10)	Base	0.41 ± 0.10	<b>0.80 ± 0.13</b>	0.30 ± 0.15	0.00 ± 0.00	
	QA-Finetuning	<b>0.49 ± 0.10</b>	<b>0.80 ± 0.13</b>	<b>0.50 ± 0.17</b>	<b>0.00 ± 0.00</b>	<b>+19.51%↑</b>
<b>Radiology</b> ( <i>N</i> = 57)	Base	<b>0.49 ± 0.04</b>	<b>0.93 ± 0.03</b>	<b>0.40 ± 0.07</b>	<b>0.05 ± 0.03</b>	
	QA-Finetuning	0.45 ± 0.04	<b>0.93 ± 0.03</b>	<b>0.40 ± 0.07</b>	0.04 ± 0.02	<b>-8.54%↓</b>
<b>Skin</b> ( <i>N</i> = 11)	Base	0.37 ± 0.08	0.91 ± 0.09	<b>0.27 ± 0.14</b>	0.00 ± 0.00	
	QA-Finetuning	<b>0.39 ± 0.10</b>	<b>1.00 ± 0.00</b>	<b>0.27 ± 0.14</b>	<b>0.09 ± 0.09</b>	<b>+4.88%↑</b>
<b>Social &amp; Preventive Medicine</b> ( <i>N</i> = 91)	Base	<b>0.44 ± 0.04</b>	0.81 ± 0.04	<b>0.34 ± 0.05</b>	<b>0.10 ± 0.03</b>	
	QA-Finetuning	0.43 ± 0.03	<b>0.89 ± 0.03</b>	0.32 ± 0.05	0.08 ± 0.03	<b>-2.52%↓</b>
<b>Surgery</b> ( <i>N</i> = 249)	Base	<b>0.41 ± 0.02</b>	0.86 ± 0.02	<b>0.35 ± 0.03</b>	<b>0.08 ± 0.02</b>	
	QA-Finetuning	0.40 ± 0.02	<b>0.88 ± 0.02</b>	0.31 ± 0.03	0.05 ± 0.01	<b>-2.93%↓</b>
<b>Unknown</b> ( <i>N</i> = 2)	Base	0.30 ± 0.30	0.50 ± 0.50	<b>0.50 ± 0.50</b>	<b>0.00 ± 0.00</b>	
	QA-Finetuning	<b>0.45 ± 0.25</b>	<b>1.00 ± 0.00</b>	<b>0.50 ± 0.50</b>	<b>0.00 ± 0.00</b>	<b>+50.00%↑</b>
<b>Overall</b> ( <i>N</i> = 2816)	Base	<b>0.42 ± 0.01</b>	0.85 ± 0.01	<b>0.35 ± 0.01</b>	<b>0.09 ± 0.01</b>	
	QA-Finetuning	0.40 ± 0.01	<b>0.88 ± 0.01</b>	0.31 ± 0.01	0.06 ± 0.00	<b>-5.10%↓</b>

1872  
1873

## M DISTANCE METRIC CHOICE FOR CONTRASTIVE NEIGHBOR SELECTION

1874  
1875  
1876  
1877  
1878  
1879

**Rationale.** We use the Gower distance because it is data-type agnostic and compares heterogeneous features (numeric, binary, categorical) without domain-specific encodings. It provides a simple, interpretable default for mixed clinical tables.

1880  
1881  
1882  
1883  
1884  
1885  
1886  
1887

**Alternatives.** The pipeline is metric-agnostic. In principle, other choices can be substituted in the neighbor retrieval step, for example: (i) scaled Euclidean on normalized numeric features with one-hot categories, (ii) Hamming distance for categorical-only subsets, (iii) cosine distance on serialized or embedded representations, or (iv) learned metrics (e.g., Mahalanobis) if one wishes to tune feature weights.

1888  
1889

**Scope.** A full comparison of distance functions is outside the scope of this paper. We adopt Gower as a simple and effective default for mixed-type data, and future work could explore learned or task-specific metrics.

## 1890 N CLINICIAN EVALUATION PROTOCOL AND RUBRIC

1891  
 1892 **Protocol.** We randomly sampled 10 supervision traces from the training corpus. Two independent  
 1893 clinicians with cardiology expertise reviewed the same set, each completing a structured rubric for  
 1894 every trace without seeing the other’s responses. Cases contained only de-identified, synthesized  
 1895 patient descriptions derived from tabular rows (anchor and neighbors). The clinicians were asked  
 1896 to rate each trace along five dimensions and optionally add a one-line comment. We report the  
 1897 normalized tallies in Tables 10–11.

1898 **Rubric (per trace).** Each trace was rated on the following dimensions with the indicated discrete  
 1899 scale.

- 1901 1. **Overall clinical plausibility:** *Yes / Partially / No.*
- 1902 2. **Unsafe or inappropriate recommendations:** *None / Minor / Concerning.*
- 1903 3. **Appropriate weighting of key factors:** *Yes / Partially / No.*
- 1904 4. **Comparative reasoning quality (why target vs. neighbor):** *Clear / Partial / Superficial.*
- 1905 5. **Uncertainty expression:** *Understated / Appropriate / Overstated.*
- 1906 6. **One-line comment (optional):** free-text note (e.g., phrasing, missing considerations).

### 1909 **Guidance provided to raters.**

- 1911 • *Plausibility* asks whether the narrative could reasonably reflect clinical reasoning given only  
 1912 the provided variables.
- 1913 • *Unsafe/inappropriate* flags any recommendation that would be clinically unsafe or clearly  
 1914 inappropriate in context; “*Minor*” covers low-risk or borderline phrasing.
- 1915 • *Weighting* assesses whether major risk factors are emphasized appropriately relative to minor  
 1916 ones.
- 1917 • *Comparative reasoning* evaluates whether differences between target and neighbors are  
 1918 identified and used to justify outcomes.
- 1919 • *Uncertainty* evaluates acknowledgment of limits of the available variables (avoid over-  
 1920 confidence or implying hidden labels).

1923 **Limitations.** This review is qualitative and small-scale ( $n=10$  traces), with no rater training or  
 1924 adjudication; results should be interpreted as a plausibility/safety check for *research-only* supervision  
 1925 rather than clinical validation or calibrated risk assessment. Importantly, we also note the high  
 1926 disagreement between the two clinicians.

Table 10: Clinician (A): tally of ratings across 10 traces.

	Positive	Partial / Minor	Negative
Plausibility	<b>5 (Yes)</b>	4 (Partially)	1 (No)
Unsafe / inappropriate	<b>7 (None)</b>	3 (Minor)	0 (Concerning)
Weighting	<b>5 (Yes)</b>	4 (Partially)	1 (No)
Reasoning	<b>5 (Clear)</b>	4 (Partial)	1 (Superficial)
Uncertainty	<b>5 (Appropriate)</b>	–	5 (Overstated)

Table 11: Clinician (B): tally of ratings across 10 traces.

	Positive	Partial / Minor	Negative
Plausibility	1 (Yes)	<b>9 (Partially)</b>	0 (No)
Unsafe / inappropriate	4 (None)	<b>6 (Minor)</b>	0 (Concerning)
Weighting	0 (Yes)	<b>8 (Partially)</b>	2 (No)
Reasoning	0 (Clear)	4 (Partial)	<b>6 (Superficial)</b>
Uncertainty	0 (Appropriate)	–	<b>10 (Overstated)</b>

## O CLINICIAN VALIDATION OF SUPERVISION TRACES

Out of the 10 randomly sampled traces, **no trace received a "Concerning" safety rating, and only one traces was judged to be implausible by Clinician (A)**. In addition to these discrete measures, we also include a table containing the qualitative feedback from Clinician (B) on 10 randomly sampled traces. Clinician (A) only had one comment, stating that "CRP should be acted on. Recommend finding the cause of CRP 45, like cancer". We therefore only include a table for Clinician (B), who had additional comments for all traces. Tags indicate recurring themes; comments are lightly abridged for brevity.

1944  
1945  
1946  
1947  
1948  
1949  
1950  
1951  
1952  
1953  
1954  
1955  
1956  
1957  
1958  
1959  
1960  
1961  
1962  
1963  
1964  
1965  
1966  
1967  
1968  
1969  
1970  
1971  
1972  
1973  
1974  
1975  
1976  
1977  
1978  
1979  
1980  
1981  
1982  
1983  
1984  
1985  
1986  
1987  
1988  
1989  
1990  
1991  
1992  
1993  
1994  
1995  
1996  
1997

Table 12: Clinician (B) qualitative review of 10 traces.

1998	2000	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026	2027	2028	2029	2030	2031	2032	2033	2034	2035	2036	2037	2038	2039	2040	2041	2042	2043	2044	2045	2046	2047	2048	2049	2050	2051
		<b>Patient</b>	<b>Issue tags</b>	<b>Clinician comment (abridged)</b>																																																
1	1	Vague phrasing; overconfidence	“BP ‘way above’ is not clinical phrasing—use concrete categories (e.g., stage 2 hypertension). Consider guideline scores (e.g., CHADS <sub>2</sub> -VASc).”																																																	
2	2	Overstates intervention benefit; weighting	“Hyperlipidemia not that serious for a non-smoking woman without diabetes, even with grade 2 hypertension.”																																																	
3	3	Speculative; conflicting factors; circular counterfactual	“Acknowledge conflict between anthropometric and biochemical factors; counterfactual goes in circles.”																																																	
4	4	Partial weighting; overconfidence	“Reasoning partial; certainty overstated given available variables.”																																																	
5	5	Baseline risk omitted	“Age not addressed correctly—baseline mortality risk.”																																																	
6	6	Counterfactual focus misaligned	“BG change not the primary modifiable variable in this context; reasoning superficial.”																																																	
7	7	Overconfidence; superficial	“Reasoning superficial; certainty overstated.”																																																	
8	8	Misinterpretation of CRP	“Elevated CRP may reflect infection—don’t treat as CVD risk alone.”																																																	
9	9	Lab inconsistency note	“Glucose/HbA1c discrepancy is often seen (e.g., after a meal).”																																																	
10	10	Risk calibration; BP control	“CVD risk overstated; emphasize blood-pressure control (cf. risk charts/guidelines).”																																																	

## P LLM USAGE

In accordance with the ICLR 2026 Author Guide, we disclose that large language models (LLMs) were used solely to assist with text polishing and minor formatting during paper preparation. LLMs were not involved in research ideation, experiment design, or result interpretation. All scientific contributions, methods, and conclusions are the work of the authors.

## Q QUALITATIVE REASONING EXAMPLES

To make the model’s internal reasoning structure transparent, we present annotated reasoning traces for a selection of representative clinical cases. These qualitative examples illustrate the structured reasoning competencies that our training objective is designed to cultivate.

In this section we include *verbatim reasoning traces* solely for interpretability and qualitative analysis. These traces are not used for training, are not exposed by the deployed model, and serve only to evaluate the reasoning behaviors emerging from our supervision scheme.

To parallel the three components introduced in Section C.3, each reasoning trace is annotated using a color-coded scheme highlighting three qualitatively distinct reasoning modes.

**Color-coding of reasoning modes.** We define three colors corresponding to the three structured reasoning behaviors encouraged by our supervision signal:

- **(1) Clinical Differentiation (Blue)**

Inspired by the *Differential Reasoning* step in our prompt design, this mode captures the model’s ability to identify clinically decisive features, contrast competing diagnoses, and articulate structured differences between plausible etiologies. It answers the question: “*Which competing explanations matter here, and how do they differ?*”

- **(2) Plausibility & Consistency Checking (Green)**

Analogous to the *Label Plausibility* step, this mode reflects the model’s ability to evaluate whether the clinical picture is internally coherent. It is checking whether symptoms, vitals, risks, and pathophysiology align. It answers: “*Does this presentation make sense, and what evidence supports or contradicts it?*”

- **(3) Priority-Based Clinical Action (Red)**

Reflecting the *Counterfactual / Action Planning* component, this mode highlights how the model resolves the case into a prioritized, causally-grounded clinical action. This is often the highest-urgency, safety-critical intervention recommended. It answers: “*Given this reasoning, what is the one intervention that must occur next?*”

**Selection of examples.** To ensure that the qualitative analysis is both fair and informative, we select questions for which the base model demonstrates non-trivial but unreliable performance (answering correctly at least 2/10 times), while the fine-tuned model answers correctly in a stable majority of

2052 runs ( $> 5/10$ ). This guarantees that the examples reflect genuine, reproducible improvements in  
2053 reasoning rather than cherry-picked successes or failures.  
2054

2055 **Purpose of qualitative examples.** The annotated traces below provide qualitative evidence that the  
2056 model: (i) performs structured differential comparisons, (ii) assesses internal clinical plausibility,  
2057 and (iii) selects prioritized interventions grounded in causal medical reasoning. These examples  
2058 are included exclusively for interpretability and are not representative of the model’s inference-time  
2059 outputs.

2060 We present first the question, then the Base model’s reasoning followed by the full Tables2Traces  
2061 reasoning.  
2062

2063

2064

2065

2066

2067

2068

2069

2070

2071

2072

2073

2074

2075

2076

2077

2078

2079

2080

2081

2082

2083

2084

2085

2086

2087

2088

2089

2090

2091

2092

2093

2094

2095

2096

2097

2098

2099

2100

2101

2102

2103

2104

2105

2106 Q.1 ACUTE HIV COMPLICATION AND EMERGENT AIRWAY COLLAPSE  
2107  
2108  
2109  
2110  
2111  
2112  
2113  
2114  
2115  
2116  
2117  
2118  
2119  
2120  
2121  
2122  
2123  
2124  
2125  
2126  
2127  
2128  
2129  
2130  
2131  
2132  
2133  
2134  
2135  
2136  
2137  
2138  
2139  
2140  
2141  
2142  
2143 Question  
2144  
2145 A 55-year-old woman with a history of HIV presents to the emergency department with  
2146 progressive dyspnea, fever, and dry cough for the past 4 days. She has not been compliant  
2147 with antiretroviral or prophylactic medication. On evaluation, the patient is in moderate  
2148 respiratory distress. The temperature is 38.8°C (102.0°F), the blood pressure is 124/82 mm  
2149 Hg, the pulse is 96/min, and the respiratory rate is 20/min. Pulse oximetry is 92% on 4 L  
2150 oxygen by nasal cannula. Her CD4 count is 180 cells/ $\mu$ L. IV antibiotics and glucocorticoids  
2151 are administered. After 30 minutes, the patient develops severe respiratory distress. Repeat  
2152 vital signs show: temperature 38.3°C (101.0°F), blood pressure 80/50 mm Hg, pulse 104/min,  
2153 respiration rate 32/min and pulse oximetry 85% on nasal cannula. The trachea deviates to the  
2154 left. Breath sounds are absent on the right side and the neck veins are distended. Telemetry  
2155 shows sinus tachycardia. Which of the following is the best next step in the management of  
2156 this patient?  
2157 A: 'Discontinue antibiotics'  
2158 B: 'Perform an arterial blood gas'  
2159 C: 'Needle thoracostomy'  
D: 'Stat chest X-ray'

2160  
2161

## Base Reasoning

2162  
2163

Okay, so I'm trying to figure out the best next step for this patient. Let's start by going through all the information given.

2164

The patient is a 55-year-old woman with HIV who presented to the emergency department with symptoms of progressive dyspnea, fever, and dry cough for four days. She hasn't been taking her antiretroviral or prophylactic medications as prescribed. That makes me think she might have an opportunistic infection because HIV can weaken her immune system.

2165

Her vital signs upon arrival are: temperature at 38.8°C (which is slightly elevated), blood pressure around 124/82 mmHg, pulse is 96 beats per minute, and respiratory rate is upped at 20 breaths per minute. Her oxygen saturation on nasal cannula at 4 L/min is down to 92%. So she's breathing harder than normal and not getting enough oxygen from just that.

2166

CD4 count of 180 cells/ $\mu$ L—this suggests her immune suppression might be moderate since CD4 counts below a certain threshold indicate more severe immunodeficiency in HIV patients; maybe she has some level of immunity left but definitely compromised.

2167

She was treated with IV antibiotics and glucocorticoids initially because those are common treatments for infections like pneumonia or something causing an inflammatory response—maybe *Pneumocystis carinii* or another bacterial infection given her history of non-compliance.

2168

But then after half an hour (30 minutes later), things took a turn for the worse: now she's in severe respiratory distress—temperature went down slightly but still febrile? Wait no—it decreased from  $\sim 39^\circ\text{C}$  to about  $\sim 38^\circ\text{C}$  which isn't too bad—but BP dropped significantly into hypotensive range (80/50) which indicates shock possibly? Pulse jumped up to 104 bpm—a tachycardia—and respiration rate doubled—to 32—which shows increasing difficulty breathing even more than before—and oxygenation dropped further despite being on higher flow (still only at nasal cannula). Also noted that trachea deviates left—that sounds like there's fluid buildup on one side making it hard to breathe; probably right-sided issue since tracheal deviation left means mediastinal shift towards left?

2169

Breath sounds absent on right side—if you can't hear lung sounds there, it could mean either complete collapse or effusion/tension pneumothorax perhaps? Neck veins distended suggest jugular venous distension—which often points towards heart failure or fluid overload leading to increased intracranial pressure if undiagnosed quickly.

2170

Telemetry shows sinus tachycardia—that's consistent with stress responses like anxiety/fear but also possible electrolyte imbalances such as low potassium/hypokalemia which causes arrhythmias including sinus tachycardia sometimes when K+ levels drop too low—or could be due directly related organ dysfunction affecting heart rhythm control centers in brainstem? So putting this together: The initial presentation points toward an acute medical condition needing prompt attention—the most likely culprit here seems like Acute Respiratory Distress Syndrome (ARDS) considering pulmonary issues alongside systemic compromise indicated by dropping BP into hypotensive ranges along with rising heart rate indicating circulatory insufficiency—but wait ARDS usually comes from direct lung injury vs indirect causes... Alternatively sepsis maybe?

2171

Alternatively thinking about *Pneumocystis jiroveci* pneumonia—is common in HIV patients when they're not compliant because their immune systems aren't controlling it well anymore especially if they missed their meds preventing PCP reactivation.

2172

Wait though—in typical cases where someone presents similarly without any other comorbidity risk factors beyond age—they'd workup would include chest X-ray first before moving onto more invasive tests.

2173

But let me think again—the question says “best” next step after these findings post-treatment changes...

2174

2175

2176

2177

2178

2179

2180

2181

2182

2183

2184

2185

2186

2187

2188

2189

2190

2191

2192

2193

2194

2195

2196

2197

2198

2199

2200

2201

2202

2203

2204

2205

2206

2207

2208

2209

2210

2211

2212

2213

2214  
2215

## Base Reasoning (continued)

2216  
2217

In terms of management steps:

2218  
2219

Option A) Discontinue antibiotics—I don't see why stop them immediately unless we know they're ineffective/mutually harmful.

2220  
2221Option B) Perform ABG—to check actual O<sub>2</sub> saturation levels accurately rather than relying on pulse oximeter readings because sometimes pulse oximetry can give false readings especially if skin perfusion poor etc.—ABG gives precise measure. Also useful info whether pH/acid-base status via blood gas.2223  
2224

Option C) Needle thoracostomy—is used mainly for tension pneumothorax where needle decompression needed rapidly... But here doesn't seem immediate need unless confirmed.

2225  
2226

Option D) Stat chest X-ray—to rule out serious conditions like massive collapse, lung opacities etc., hence imaging needed.

2227  
2228

Given all above—what happened after treatment leads us closer—are we missing something else? After starting IV abx + steroids got worse—not better—as opposed expected improvement seen typically wouldn't happen so quickly except maybe progression until correct therapy found.

2230  
2231

Maybe underlying cause needs confirmation—with worsening clinical picture pointing towards bacterial etiology requiring different approach.

2232  
2233

Another angle: If CD4 count is &gt;200 usually considered advanced disease state—an indication that full-blown AIDS-related complications should already be managed accordingly... Or does lower CD4 imply less likely ability respond effectively without supportive care?

2234  
2235Considering time frame—from ED evaluation onward: They gave IV abx + glucocorticoids hoping treating community-acquired pneumonia/pneumonia caused by *Streptococcus/H. influenzae/Pseudomonas* etc.; however rapid decline suggests either wrong choice meds OR presence of MDR-TB/HIV-associated tuberculosis/*Legionella/Mycoplasma*... Especially TB commonly occurs latently becoming active due lack adherence HAART leading backsliding...2236  
2237

If suspected TB would require appropriate susceptibility testing/bigger guns—in ED setting assuming availability limited though.

2238  
2239

So what do I do now:

2240  
2241

1st thought – get imaging done stat via CXR prior proceeding further tests—as ABCDs offer various options;

2242  
2243

Now looking at choices:

2244  
2245

A–D provided. B says perform ABG—important data point but not definitive treatment; D stat CXR—essential diagnostic tool.

2246  
2247

Which between B &amp; D?

2248  
2249

Additionally, could consider doing both—but among options given only choose one option. Assuming question asks best next step regardless previous tx outcome.

2250  
2251

Possibly ruling out life-threatening issues requires seeing CXR first—even if started tx early—you'd want confirm diagnosis correctly.

2252  
2253

Thus answer D)—stat chest xray—

2254  
2255

However alternative reasoning arises—tracheal deviation implies possible mass lesion pushing diaphragm upwards compressing opposite lung fields thus limiting sound transmission meaning underdiagnosed collapsed lungs → necessitating immediate intervention else risk aspiration/collapse.

2256  
2257

Wait—if breath sounds absent right side implying total collapse/right main stem intubation required? No—heavily depends how critical situation—attempted intubation may complicate matters further...

2258  
2259

Alternative line of thought: Trauma/Bleeding/Tamponade—but unlikely context-wise w/o trauma hx. Pulmonary embolism—risk factors high VTE = age, female, hormones, HIV-associated hypercoagulability potentially...

2260  
22612262  
22632264  
22652266  
2267

2268

2268  
2269

## Base Reasoning (continued)

2270

Hmm.. Maybe go back basics:

2271

The key labs mentioned were Trachea deviates Left → probably Right Main Bronchus obstruction/stenosis/trouble breathing → could also indicate central airway obstruction requiring bronchoscopy/endoscopic procedures BUT again timing concerning urgency during acute episode.

2272

Alternately, mass lesion impinging on airway causing shift ⇒ dyspnea/stridor/wheezing heard over affected area—not sure description said Breath Sounds Absent though—so no wheezes/sounds → suggestive of no air movement → complete collapse/lung deflation → indicative of massive PE?, TPA blockage, malignancy compression, tumour obstructing major bronchi, etc.—all possibilities.

2273

But how urgent is it? Can you manage without knowing precisely while waiting for tests? Well, Chest X-ray will show opacity or not, pneumoconiosis, bronchiectasis, pneumonia, wedge-shaped opacity... In case of abscess, large bullae etc. Alternatively CT scan offers better detail, but “stat” refers to fastest available method—CXR provides quick insight.

2274

Therefore, the Best Next Step Would Be performing Stat Chest X-Ray to determine underlying pathology definitively guiding subsequent management decisions regarding specific treatment approaches, such as antivirals, antibiotics tailored based on cultures, further specialist referral, intubation if necessary...

2275

Yes, I think Option D) Stat Chest X-ray Is The Best Next Step After Initial Treatment Didn't Yield Improvement And With Worsening Symptoms.

2276

The best next step in managing this patient's condition would be conducting a **stat chest X-ray**. This diagnostic tool will provide crucial information about potential pathological processes affecting the lungs and surrounding areas following initial antibiotic and glucocorticoid administration failing to improve symptoms promptly. Given the clinical presentation—including tracheal deviation indicating possible airway obstruction—the STAT CXR helps differentiate between conditions such as pneumonia, consolidation, masses/tumors compressing airflow pathways versus other critical scenarios requiring immediate intervention like tension pneumothorax or mechanical ventilation considerations once stabilised otherwise.**Answer: D**

2277

2278

2279

2280

2281

2282

2283

2284

2285

2286

2287

2288

2289

2290

2291

2292

2293

2294

2295

2296

2297

2298

2299

2300

2301

2302

2303

2304

2305

2306

2307

2308

2309

2310

2311

2312

2313

2314

2315

2316

2317

2318

2319

2320

2321

2322  
2323

## Tables2Traces Reasoning

2324  
2325  
2326  
2327  
2328  
2329  
2330

The question presents a 55-year-old woman with HIV who has been non-compliant with antiretroviral and prophylactic medications. She presents to the emergency department with progressive dyspnea, fever, and dry cough for the past 4 days. Her vital signs indicate moderate respiratory distress, and she is in severe respiratory distress after receiving IV antibiotics and glucocorticoids. The patient's CD4 count is low at 180 cells/ $\mu$ L, which suggests that her immune system may be compromised due to poor management of her HIV infection.

2331  
2332  
2333

Given this information, the differential strongly includes an opportunistic infection such as *Pneumocystis jirovecii* pneumonia (PJP), which is common in patients with advanced HIV or inadequate prophylaxis.

2334  
2335

Now let's break down your options:

2336  
2337

Option A: Discontinue antibiotics — This option would be inappropriate because there is no evidence of antibiotic resistance or a contraindication to continuing treatment.

2338  
2339  
2340

Option B: Perform an arterial blood gas — An ABG provides useful information about oxygenation and acid–base status, but would not address the primary, rapidly deteriorating complication suspected here.

2341  
2342  
2343

Option C: Needle thoracostomy — The unilateral absence of breath sounds together with tracheal deviation is clinically consistent with a tension pneumothorax, a life-threatening complication that can occur during assisted ventilation.

2344  
2345  
2346

Given these findings, the most urgent and appropriate next step is needle thoracostomy (Option C), as immediate decompression is required to relieve trapped intrapleural air and prevent cardiovascular collapse.

2347  
2348  
2349

Although a chest X-ray could confirm the diagnosis, waiting for imaging would delay a time-critical, life-saving intervention.

Answer: C

2351  
2352  
2353  
2354  
2355  
2356  
2357  
2358  
2359  
2360  
2361  
2362  
2363  
2364  
2365  
2366  
2367  
2368  
2369  
2370  
2371  
2372  
2373  
2374  
2375

2376 Q.2 MULTISYSTEM INFECTION WITH ATYPICAL FEATURES  
2377  
2378  
2379  
2380  
2381  
2382  
2383  
2384  
2385  
2386  
2387  
2388  
2389  
2390  
2391  
2392  
2393  
2394  
2395  
2396  
2397  
2398  
2399  
2400  
2401  
2402  
2403  
2404  
2405 Question  
2406  
2407 A 57-year-old man presents to the emergency department with confusion. His symptoms  
2408 started a few days ago and have been gradually worsening. Initially, the patient had a fever and  
2409 a cough which has progressed to abdominal pain, diarrhea, and confusion. His temperature is  
2410 102°F (38.9°C), blood pressure is 127/68 mmHg, pulse is 120/min, respirations are 17/min,  
2411 and oxygen saturation is 94% on room air. Physical exam is notable for localized crackles and  
2412 decreased breath sounds in the left lower lung field. The patient is confused and is answering  
2413 questions inappropriately. Laboratory studies are ordered as seen below.  
2414 Hemoglobin: 12 g/dL  
2415 Hematocrit: 36%  
2416 Leukocyte count: 16,500/mm<sup>3</sup> with normal differential  
2417 Platelet count: 190,000/mm<sup>3</sup>  
2418 Serum:  
2419 Na<sup>+</sup>: 130 mEq/L  
2420 Cl<sup>-</sup>: 100 mEq/L  
2421 K<sup>+</sup>: 4.3 mEq/L  
2422 HCO<sub>3</sub><sup>-</sup>: 25 mEq/L  
2423 BUN: 20 mg/dL  
2424 Glucose: 99 mg/dL  
2425 Creatinine: 1.1 mg/dL  
2426 Ca<sup>2+</sup>: 10.2 mg/dL  
2427 Which of the following is the best diagnostic test to guide current therapy in this patient?  
2428 A: 'Chest radiography'  
2429 B: 'Lung biopsy'  
C: 'Sputum culture'  
D: 'Urine antigen test'

2430  
2431

## Base Reasoning

2432  
2433  
2434  
2435

Okay, so I'm trying to figure out the best diagnostic test for this patient. Let's see, he's a 57-year-old man with confusion and other symptoms like fever, cough, abdominal pain, and diarrhea. His vital signs show a low-grade fever (102°F), tachycardia (pulse 120), and slightly decreased oxygen saturation.

2436  
2437  
2438  
2439

Looking at his physical exam: crackles in the left lower lung field suggest some pulmonary issue—maybe pneumonia or something else like an infection affecting his lungs. The decreased breath sounds there could mean fluid buildup or consolidation.

2440  
2441  
2442  
2443

His lab work shows hemoglobin is normal but hematocrit is low at 36%. That makes me think about possible causes of anemia—could be from blood loss or bone marrow issues. Leukocyte count is high at 16,500/mm<sup>3</sup> with a normal differential; that might indicate infection since WBCs are upping their production.

2444  
2445  
2446  
2447

Serum electrolytes: sodium is within normal range but chloride's also okay. Potassium is slightly on the lower side (4.3 mEq/L). BUN isn't too high which suggests it's not severely dehydrated because BUN usually goes up when you're dehydrated as your body breaks down proteins for energy during fasting periods.

2448  
2449  
2450  
2451

He has hyperglycemia here with glucose of 99 mg/dL—that's just above normal ranges; maybe stress from infection can cause elevated blood sugar levels even without diabetes being present previously known? Or perhaps undiagnosed DM?

Creatinine of 1.1 mg/dL isn't super high—it doesn't point towards kidney failure directly unless accompanied by more concerning symptoms like hypertension or edema elsewhere in history—but nothing mentioned about that here.

2452  
2453  
2454

The question asks what test to guide current therapy now though—the key thing right now seems to be figuring out what's causing his confusion and possibly guiding treatment based on specifics found in labs or imaging.

#### Step-by-step Explanation:

2455  
2456  
2457  
2458  
2459  
2460  
2461  
2462  
2463  
2464

The patient presents with acute onset confusion alongside respiratory symptoms such as fever and cough progressing into abdominal discomfort along with diarrhea—a picture consistent with an infectious process given the timeframe of symptom progression (likely viral vs. bacterial etiology). His lab results include normocytic anemia (hematocrit 36%), mild leukocytosis suggesting neutrophilia indicative of inflammation/infection rather than chronic conditions like leukemia (given age < 60 typically seen more commonly in chronic forms), hyperglycemia possibly due to stress response despite no prior diagnosis of diabetes mellitus (needing further evaluation if follow-up glucose levels confirm trends toward poor glycemic control), hypokalemia may require attention depending on clinical context especially if ECG changes noted (though not provided here).

2465  
2466  
2467

Physical exam findings localized crackles/lower lung fields hint at bronchial obstruction or consolidation, likely pointing towards pneumonia or bronchitis, requiring chest imaging for confirmation via CXR before proceeding further into advanced testing options listed:

2468  
2469  
2470  
2471  
2472  
2473  
2474

- **Chest Radiography:** Most appropriate next step given physical exam indicating potential pulmonary focus and need to rule out complications such as effusion/pneumonia which would inform subsequent management decisions regarding antibiotic choice.
- **Sputum culture:** Useful initially but typically after confirmed suspicion from CXR.
- **Urine antigen test:** More relevant for certain infections like UTI or MRSA if urinary sources considered.
- **Lung biopsy:** Only indicated if definitive diagnosis is necessary after CXR/CT/ultrasound rule out other possibilities.

2475  
2476  
2477  
2478  
2479

Thus, chest X-ray provides immediate guidance essential before moving onto more invasive or expensive tests, ensuring efficient use of resources while addressing the underlying condition promptly.

2480  
2481  
2482  
2483

**Answer: A) Chest radiography**

2484  
2485

## Tables2Traces Reasoning

2486  
2487  
2488  
2489

Okay, let's tackle this question step by step. First off, I need to understand what's going on with this 57-year-old man who came into the emergency department with confusion. His symptoms started a few days ago as fever and cough but have progressed into abdominal pain, diarrhea — which makes me think maybe he has some kind of gastroenteritis now too.

2490  
2491  
2492  
2493

Looking at his vitals: temperature is 102°F (38.9°C), blood pressure normalish at 127/68 mmHg pulse rate up at 120/min respirations are low-normal at 17/min though oxygen saturation drops slightly down to room air level (94%). Physical exam shows crackles in left lower lung field so there might be some lung issues here.

2494  
2495  
2496  
2497  
2498

His labs show elevated WBC count-16k/mm<sup>3</sup>-which is high enough that they did check differential but found it normal? Wait nope correction: "Leukocyte count: 16K/mcV" wait no-the user said leukocyte count was "normal differential". So even though total WBCs are up higher than usual range typically around say <10-20 maybe?), but differentials were okay so probably reactive increase?

2499  
2500  
2501  
2502  
2503

Serum markers include sodium levels within normal ranges except bicarbonate being low-normal (25 mEq/L). BUN is elevated at mg/dL which could indicate dehydration or other kidney stressors given creatinine also slightly elevated—1.1 mg/dL-but still within stage G2 CKD range perhaps? Glucose levels look okay glucose just under fasting normoglycemic cutoffs usually around <100mg/dL fasting).

2504  
2505  
2506  
2507

Ca2+ very high at over-the-top serum calcium levels-10.2 mg/dL-that's hypercalcemia territory because typical reference ranges are about 8-12 mg/dL depending on lab norms; so above mid-normal might be considered borderline high risk here.)

2508  
2509

So putting together these findings plus recent onset febrile illnesses progressing through GI distress...

2510

Now looking for best diagnostic tests available options:

2511  
2512

Option A: Chest radiography-to assess lungs since he had crackles left lower lobe possibly indicative of pneumonia if present.

2513  
2514  
2515

Option B:Lung biopsy-isn't necessary yet unless there's signs like abscess formation etc., especially when considering treatment options first via antibiotics before resorting invasive measures

2516  
2517

Option C:Sputum culture-to detect presence bacteria such as Legionella pneumoilia-if you suspect based on clinical picture

2518  
2519  
2520

But option D says Urine antigen test—a quick non-invasive way checking for presence antibodies against Leggiella specifically via ELISA-like assays known effective & rapid method compared cultures needing time incubation

2521  
2522  
2523  
2524  
2525  
2526  
2527  
2528  
2529  
2530  
2531  
2532  
2533  
2534  
2535  
2536  
2537

2538  
2539

## Tables2Traces Reasoning (continued)

2540

Key points why D better choice than others:

2541

1.) Clinical suspicion already leaning towards Legionnaires' Disease given progressive nature from URTI into GI then central nervous system changes leading us toward likely etiology making testing efficient

2542

2.) High specificity/sensitivity ratio between urinalysis-based tests vs traditional sputum cultures where false negatives/negatives common due variability handling infectious particles during collection process)

2543

3.) Rapid results critical when dealing urgent situations where prompt treatment needed e.g., IV ceftriaxone + azithromycin combo standard treatments guidelines recommend empiric use pending confirmation followed by switching after knowing causative agent)

2544

4) Other factors mentioned-allergic reactions avoidance contraindications ruled out etc.-so no contraindication using urine Ag testing either

2545

Therefore among all choices presented most appropriate next step confirming suspected diagnosis while avoiding more invasive procedures initially thus guiding appropriate antibiotic selection/titration thereby improving outcomes chances.

2546

Another angle thinking about how each option impacts immediate care decisions-instant results give actionable info whereas chest X-ray takes longer hours/day potentially delaying initiation proper antimicrobial therapy possibly increasing mortality risks

2547

Also note that hypocalcemia isn't part presented data contradicting initial assessment since  $\text{Ca}^{2+}$  actually quite high-a point conflicting possibility unrelated condition causing similar symptomatology?

2548

Wait original query mentions "fever", "abdominal pain", "diarrhea", "confusion" progression alongside abnormal labs including hypocalcemia? No-the serum  $\text{Na}^+$ ,  $\text{Cl}^-$ ,  $\text{K}^+$  all seem stable except  $\text{HCO}_3^-$  being low end-of-range—but  $\text{Ca}^{2+}$  over top end pointing towards hyperparathyroidism/hyperplasia-induced hypercalcemia instead contributing factor complicating things-but assuming primary issue remains undiagnosed yet related pathogen-driven cause rather secondary causes...

2549

Thus sticking focus areas remain focused upon ruling out infective etiology hence rationale behind selecting urine Antigen Test stands solid.

2550

Final conclusion aligns answer D

2551

2552

2553

2554

2555

## Q.3 ACUTE CHOLINERGIC TOXICITY FROM ENVIRONMENTAL EXPOSURE

2556

2557

2558

2559

2560

2561

2562

2563

2564

2565

2566

2567

2568

2569

2570

2571

2572

2573

2574

2575

2576

2577

2578

2579

2580

## Question

2581

A 45-year-old mechanic presents to the emergency department complaining of acute-onset shortness of breath while repairing a plowing tractor for his neighbor. The patient denies having any history of asthma or respiratory symptoms, and does not smoke. His temperature is 99.8°F (37.7°C), pulse is 65/min, blood pressure is 126/86 mmHg, and respirations are 20/min. His oxygen saturation is 97%. On exam, he is pale and diaphoretic. His pupils are contracted. Diffuse wheezes are noted in all lung fields. What is the best treatment for his condition?

2582

A: 'Succinylcholine'

2583

B: 'Inhaled ipratropium and oxygen'

2584

C: 'Atropine and pralidoxime'

2585

D: 'Inhaled albuterol and oxygen'

2586

2587

2588

2589

2590

2591

2592  
2593

## Base Reasoning

2594

Okay, so I'm trying to figure out the best treatment for this 45-year-old mechanic who came in with acute-onset shortness of breath. Let's break it down step by step.

2595

First, his main complaint is sudden shortness of breath while working on a tractor. He doesn't have a history of asthma or other respiratory issues and doesn't smoke, which might lower my suspicion for typical asthma triggers like allergies or smoking-related causes.

2596

His vital signs show a slightly elevated temperature (99.8°F), tachycardia at 65 bpm, blood pressure is within normal range but maybe slightly low diastolic (86 mmHg). His respiratory rate is upped at 20 per minute because he's breathing faster than normal. Oxygen saturation is 97%, which isn't drastically low but could indicate mild hypoxia given his symptoms.

2597

On exam, he looks pale and sweating—a sign that his body might be compensating from some kind of stress or anxiety perhaps? His pupils are contracted; that makes me think about possible nervous system stimulation—maybe something like anaphylaxis causing constriction in airways?

2598

He has diffuse wheezing all over the lung fields. Wheezing can point towards bronchial obstruction—so either asthmatic in nature or maybe due to another condition like COPD if there was a previous history, but since he denies any such history... Hmm.

2599

Wait though—he's never had asthma before and no other respiratory issues mentioned except this episode during physical exertion while plowing the tractor. So more likely an acute issue leading to bronchial spasm rather than chronic disease unless there's something else going on.

2600

The options given are:

2601

A) Succinylcholine: That's usually used as an intubation agent—it's a muscle relaxant often used during surgery when you need paralysis because it affects the neuromuscular junction quickly but stops breathing too if not monitored properly.

2602

B) Inhaled ipratropium and oxygen: Ipratropium is an anticholinergic drug commonly used for COPD exacerbations because it helps with bronchodilation by relaxing smooth muscles around airways.

2603

C) Atropine and pralidoxime: Atropine can also be used similarly as ipratropium for COPD patients—it reduces secretions through its anticholinergic effect—but pralidoxime isn't typically first-line here unless specific indications apply.

2604

D) Albuterol inhaler plus oxygen: Albuterol (a beta-agonist) works well for reversible airflow obstruction like asthma attacks by dilating airways directly; adding O<sub>2</sub> would help correct hypoxia if present beyond what ambient air provides.

2605

Given that he presented after physical exertion—that points toward exercise-induced bronchoconstriction possibly? Or maybe just increased effort causing some kind of reflex reaction without underlying disease—if so then albuterol should work better since it addresses direct receptors causing tightness via beta-blockade/bronchodilation without needing corticosteroids right away unlike steroids take longer to act.

2606

But wait—the fact that his pupils are contracted suggests increased intracranial pressure? No wait—intracranial hypertension causes papilledema though not necessarily pupil changes much unless related somehow indirectly... Maybe tension pneumothorax? But no chest trauma wasn't mentioned...

2607

Alternatively could be anxiety-related hyperventilating leading him into autonomic overload—but again wheezing wouldn't fit neatly into anxiety alone generally presents differently...

2608

Another angle: Is there any possibility this person experienced angioedema especially post-exertion—which sometimes involves upper airway edema requiring treatments targeting histamines—and thus may benefit from H1 blockers alongside—or even epinephrine?

2609

Wait none of those options include H1 blockers specifically—they don't match exactly with what's provided here...

2610

2611

2612

2613

2614

2615

2616

2617

2618

2619

2620

2621

2622

2623

2624

2625

2626

2627

2628

2629

2630

2631

2632

2633

2634

2635

2636

2637

2638

2639

2640

2641

2642

2643

2644

2645

2646  
2647

## Base Reasoning (continued)

2648

So backtracking—since we're limited to these four choices:

2649

If we suspect reversible airflow obstruction whether due to asthma-like attack or perhaps acute bronchospasm triggered by exercise—he'd get good relief from albuterol via nebulizer along with oxygen support as needed until things settle down; alternatively ipratropium/beta agonists together can provide quicker action sometimes combined approaches may work better depending on individual response times.

2650

Atropic derivatives have different onset times—Ipratropium takes longer (~30 minutes) whereas albuterol acts quicker (~15–30 minutes)—so depending on how severe the patient feels they'd prefer one over others.

2651

Also considering comorbidities—he has high BP—isn't hypertensive crisis presenting now? Blood pressure being around mid-normal range actually—not super high—if anything slight elevation noted earlier vs current reading shows BP = 126/86 which seems okayish—not sure how relevant that ties in yet.

2652

Pupil contraction could relate more closely with febrile illnesses where hyperthermia leads to body responses—for example meningitis presenting—with associated rigors hence producing diaphoresis etc., but temp was only slightly above normal so less likely bacterial infection immediately comes mind unless viral cause...

2653

Putting all together—the most straightforward approach would probably be using quick-acting beta-agonist + O<sub>2</sub> as option D says.

2654

The best treatment based on the analysis aligns with using **inhaled albuterol** along with oxygen therapy due to its rapid effectiveness in addressing acute-onset reversible airflow obstruction commonly seen in conditions like exercise-induced asthma or acute bronchospasm episodes without evidence pointing towards chronic conditions such as COPD necessitating long-term medications like ipratropium bromide extended-release tablets daily every eight hours plus tiotropium bromide twice daily.

**Answer: D**

2655

2656

2657

2658

2659

2660

2661

2662

2663

2664

2665

2666

2667

2668

2669

2670

2671

2672

2673

2674

2675

2676

2677

2678

2679

2680

2681

2682

2683

2684

2685

2686

2687

2688

2689

2690

2691

2692

2693

2694

2695

2696

2697

2698

2699

2700  
2701

## Tables2Traces Reasoning

2702

Okay, let's tackle this medical question. So, the patient is a 45-year-old mechanic who suddenly developed shortness of breath while repairing a plowing tractor for his neighbor. He doesn't have a history of asthma or respiratory issues and doesn't smoke. His vital signs are mostly within normal ranges except for being pale and diaphoretic with contracted pupils. The exam shows diffuse wheezes in all lung fields.

2703

First off, I need to figure out what's causing his sudden onset symptoms. The key here might be the context—the mechanical equipment he was working on could involve exposure to some toxic substance that led to an acute reaction.

2704

Looking at the options:

2705

Option A: Succinylcholine is typically used as anesthetic agent but can cause hyperkalemia if there's underlying muscle weakness or paralysis.

2706

Option B: Inhaled ipratropium and oxygen—ipratropium is an anticholinergic medication often used in COPD or asthma attacks by relaxing bronchial smooth muscles.

2707

Option C: Atropine and pralidoxime—isotretinoin? Wait, no—pralidoxime is used after exposure to organophosphate pesticides because it helps reverse their effects by binding acetylcholinesterase inhibitors again.

2708

Wait, option C says "Atropine and pralidoxime." Atropine would be given if someone has been poisoned with something like nerve agents (organophosphates) which inhibit cholinesterases leading to overstimulation of muscarinic receptors causing various symptoms including miosis (constricted pupils), sweating (diaphoresis), bradycardia/dyspnea due to increased vagus tone affecting heart rate and airway constriction.

2709

Given that he presented with contracted pupils (miosis) along with diaphoresis... diffusing wheezing points towards bronchoconstriction—a common symptom post-organophosphate poisoning where patients develop excessive secretions from glands stimulated by acetylcholine excess since they can't break down anymore.

2710

So putting it together—if he came into contact with organochloride insecticides... then giving atropine would help manage acute cholinergic crisis caused by these substances blocking enzymes necessary for breaking down acetylcholine leading to overstimulation of the parasympathetic system... seen as wheezing plus difficulty breathing—which matches this patient's presentation.

2711

...better than just using albuterol alone wouldn't address both central nervous system involvement from ChE inhibitor toxicity nor correct pupil size directly; hence treatment should include both antagonizing muscarinic receptors via anticholinergics like ipratropium bromide alongside addressing the underlying enzyme inhibition issue either way adding pralidoxime may help restore function more effectively long-term once initial life-saving measures are done.

2712

Therefore Option C makes sense considering risk factor profile & clinical findings matching expected tox ingestion/dermal exposure likely during work incident.

2713

Answer: C

2714

2715

2716

2717

2718

2719

2720

2721

2722

2723

2724

2725

2726

2727

2728

2729

2730

2731

2732

2733

2734

2735

2736

2737

2738

2739

## Q.4 EARLY-ONSET NEURODEGENERATIVE DISEASE WITH GENETIC RISK

2740

2741

2742

## Question

2743

A 39-year-old man is brought to the physician by his wife because of personality changes over the past year. He has become increasingly irritable, loud, aggressive, and impulsive. His wife also reports jerky movements of his limbs and trunk for the past few months. His father had dementia in his mid-40s, but the details of his condition are unclear. The patient appears restless. Examination shows irregular movements of the extremities and twitching of the face and tongue. Mental status examination shows impaired memory. This patient's condition is most likely associated with which of the following changes on MRI?

2744

A: 'Reduced hippocampal volume'

2745

B: 'Multiple cortical and subcortical infarctions'

2746

C: 'Degeneration of the frontal and temporal lobes'

2747

D: 'Atrophy of the striatum'

2754  
2755

## Base Reasoning

2756  
2757

Alright, so I'm trying to figure out this medical question. Let me start by reading it carefully. The patient is a 39-year-old man brought in by his wife because of personality changes over the past year. His symptoms include becoming more irritable, loud, aggressive, and impulsive. She also mentions that he's been having jerky movements of his limbs and trunk for a few months now. His father had dementia in his mid-40s but the specifics aren't clear.

2760  
2761

On exam, he appears restless with irregular movements in his extremities and twitching face and tongue. Mental status shows impaired memory.

2763  
2764

So what condition does this point towards? The options are A through D: reduced hippocampal volume; multiple cortical/subcortical infarctions; frontal/temporal lobe degeneration; or striatal atrophy.

2765  
2766

First thought: He has movement issues—jerky movements suggest something like tremors or chorea maybe? And personality changes could be due to brain changes affecting emotional regulation areas like the frontal lobes or limbic system (like temporal lobes). Impaired memory points towards hippocampus involvement since that's where memories are stored.

Looking at each option:

2770

A) Reduced hippocampal volume—this makes sense because if there's damage there, you get memory loss which matches impaired mental status.

2772

B) Multiple infarctions would cause stroke-like issues but might present with sudden onset neurological deficits rather than gradual personality change unless it's from small vessel disease causing chronic issues.

2774

C) Frontal-temporal degeneration can lead to behavioral problems like irritability and impulsivity as well as physical tics/twitching since these areas control behavior.

2775

D) Striatal atrophy relates more to movement disorders like parkinsonism (tremors), which fits some signs here too—but not sure about the cognitive aspects much except maybe mood swings?

2779

But wait—he's showing both movement disorder (jerky movements) along with cognitive/mood issues (personality change). So either C or B could fit depending on whether it's neurodegenerative vs vascular causes.

2782

His age is 39—it's young for most neurodegenerative diseases except things like frontotemporal dementia which can affect younger people sometimes but less commonly than others. Also considering possible reversible causes first—if MRI shows anything specific...

2785

If thinking about structural brain lesions causing both motor symptoms via basal ganglia/striatum involvement plus cognitive/memory loss via hippocampus... Hmm... Maybe multiple lacunes indicating small vessel disease leading to both cerebrovascular accidents involving these regions?

2788

Wait no—the question says “most likely associated” implying perhaps an underlying condition linked directly without necessarily being acute infarction unless specified otherwise given time frame over a year suggests possibly progressive conditions rather than acute strokes causing sudden onset after onset last few months wouldn't align with progression over a year without further info on how long ago they started noticing those effects initially though).

2793

2794

2795

2796

2797

2798

2799

2800

2801

2802

2803

2804

2805

2806

2807

2808  
2809

## Base Reasoning (continued)

2810  
2811  
2812  
2813

Alternatively, multiple subcortical infarcts may result from hypertension/other vascular risk factors leading to deep white matter disease—which affects executive function including decision-making hence irritability etc., plus physical slowing down but here he seems agitated instead of slowed so maybe not purely vascular either way...

2814  
2815  
2816

I'm getting stuck between B & C again based on presentation combining behavioral/cognitive decline alongside extrapyramidal signs pointing toward striatum while also possibly involving limbic structures affecting memory.

2817  
2818  
2819  
2820

Another angle: If MRI findings are needed then let me think what each corresponds: Reduced hippocampal volume usually seen in Alzheimer-type dementias especially AD—is that common at 39? Early-onset AD rare under 40 typically presents later around their 60s–70s so less likely here unless another type e.g., familial forms exist but still uncommon enough probably not best answer choice A isn't top pick right away.

2821  
2822  
2823

Multiple subcortical infarctions would indicate probable ischemia—maybe related to hypertension/vascular dementia—but again linking behaviors better known for focal neurological deficits rather than prominent psychological ones beyond just attention/concentration.

2824  
2825  
2826  
2827

Frontal-temporal lobe degeneration often presents with apathy/irritability and hyperactivity/tactlessness—called frontotemporal dementia—characterized by early socially inappropriate behavior, etc., and FTD can have associated motor signs such as alien hand syndrome or akinetic mutism initially before progressing into severe disorientation.

2828  
2829  
2830

Striatum atrophy—as mentioned earlier linked more closely with Parkinson-like syndromes where rigidity, tremor, and bradykinesia dominate—not matching all presented features equally well.

Given all this I lean toward frontal-temporal processes.

2831  
2832  
2833  
2834  
2835

The patient exhibits symptoms indicative of frontotemporal lobe dysfunction manifesting through altered behavior patterns such as irritability and impulsivity along with motor disturbances suggesting basal ganglia involvement—a hallmark feature compatible primarily with frontotemporal degenerative processes rather than other listed options provided.

**Answer: C**

2836  
2837  
2838  
2839  
2840  
2841  
2842  
2843  
2844  
2845  
2846  
2847  
2848  
2849  
2850  
2851  
2852  
2853  
2854  
2855  
2856  
2857  
2858  
2859  
2860  
2861

2862  
2863

## Tables2Traces Reasoning

2864  
2865  
2866  
2867  
2868

Okay, let's tackle this question. So, the patient is a 39-year-old man with personality changes over the past year—irritable, loud, aggressive, impulsive. His wife also mentions jerky movements in his limbs and trunk for a few months now. His father had dementia in his mid-40s but details are unclear. The physical exam shows restlessness and irregular movements of extremities and twitching face/tongue. Mental status shows impaired memory.

2869  
2870

First off, I need to figure out what condition this could be based on symptoms and family history clues.

2871  
2872  
2873  
2874

The key here might be the combination of sudden onset of personality changes (like irritability), impulsivity which can indicate mood disorders or neurological conditions like Tourette syndrome maybe? But then there are motor symptoms too—the jerky limb movements suggest something more than just mood issues.

2875  
2876

Wait, he has facial and tongue twitches as well as limb movements—that sounds like tics or chorea maybe? Chorea is involuntary movement that looks like dance-like steps... Could it be Huntington's disease?

2877  
2878  
2879  
2880  
2881  
2882  
2883

But wait his father had dementia at mid-40s—is Huntington's hereditary? Yes! Because HD typically presents between 35-50 years old due to dominant CAG trinucleotide repeats leading to neuronal loss especially in basal ganglia structures involved in movement control. So if dad had early-onset HD presenting with similar features (dementia plus motor signs), then son might have inherited it despite being younger age presentation-wise because they haven't yet reached typical age for manifesting full-blown symptoms—maybe preclinical stage?

2884  
2885  
2886  
2887

In terms of MRI findings: In HD patients show degeneration primarily affecting caudate nucleus (part of striatum) along with putamen since these areas handle dopamine transmission regulation which becomes compromised when dopaminergic neurons die off from lackluster function due to mutant huntingtin protein accumulation causing neurotoxicity.

Looking at options:

2888  
2889  
2890  
2891

A) Reduced hippocampal volume – more associated with Alzheimer's type dementias where medial temporal lobe sclerosis occurs leading to reduced volume

B) Multiple cortical/subcortical infarctions – stroke-related damage patterns unlikely given no mention; possible but not directly linked

C) Degeneration frontal/temporal lobes – commonality across many dementias including frontotemporal disorders but less specific than striatal involvement

**D) Atrophy/striatum - yes! Striatum includes caudate/putamen; their atrophy would fit better given association w/Huntington's disease via basal ganglia involvement**

**Therefore answer D makes sense.**

Answer: D

2897

2898

2899

2900

## Q.5 CHRONIC INFLAMMATORY BOWEL DISEASE PATTERN RECOGNITION

2901

2902

2903

## Question

2904

A 41-year-old man presents to the clinic with the complaints of abdominal discomfort and cramping for the past 4 months. He also mentions that he has grossly bloody stool and most of the time an urge to defecate. He has a history of bulimia with laxative abuse several years ago. He admits having lost about 5 lb in the past month. His temperature is 37° C (98.6° F), respiratory rate is 15/min, pulse is 77/min, and blood pressure is 105/86 mm Hg. On physical examination, a mild conjunctival pallor is evident, and the rectum is erythematous, indurated, and tender. Colonoscopy demonstrates continuous mucosal lesions throughout the rectum to the hepatic flexure of the colon. What is the most likely diagnosis?

2905  
2906  
2907  
2908  
2909  
2910  
2911  
2912  
2913  
2914  
2915

- A: 'Ulcerative colitis'
- B: 'Celiac disease'
- C: 'Irritable bowel syndrome'
- D: 'Crohn's disease'

2916  
2917

## Base Reasoning

2918  
2919

Okay, so I'm trying to figure out the diagnosis for this 41-year-old man with a bunch of symptoms. Let's see... He has been having abdominal discomfort and cramping for about four months now. That's a pretty long time, so it's not something that just happened suddenly.

2920  
2921

He also mentions having grossly bloody stool, which is pretty concerning. Blood in the stool can indicate several things like hemorrhoids or maybe something more serious like colitis or colorectal cancer. Then he says he has an urgent need to defecate most of the time—that sounds like diarrhea because you usually feel that urgency when you have loose stools.

2922  
2923

He used to have bulimia and was abusing laxatives a few years ago. Bulimia can cause issues with his digestive system, maybe leading to inflammation or irritation in his intestines over time. Laxative abuse might further irritate his gut as well, causing more problems.

2924  
2925

His vital signs are slightly elevated blood pressure at 105/86 mmHg but otherwise stable—temperature is normal at 98.6°F (37°C), respiratory rate is within normal range at 15/min, pulse is okay too at 77/min.

2926  
2927

On physical exam, there's mild conjunctival pallor—which means he might be anemic—but nothing else stands out except for rectal findings: erythematous (redness), indurated (swollen), and tender rectum. So those are classic signs of proctitis—flammation in the rectum lining. The colonoscopy showed continuous mucosal lesions from the rectum all the way up to the hepatic flexure of the colon—that's higher up than usual; typically sigmoidoscopy looks only partway up if done via anoscope or flexible scope limited by anatomy.

2928  
2929

The patient presents with chronic symptoms including abdominal discomfort, cramping for four months; bloody stool indicative of gastrointestinal bleeding; urgency upon defecation suggesting diarrhea; history of bulimia and laxative use potentially contributing GI irritation; stable vitals despite mild BP elevation; physical exam shows redness/swelling/tenderness in rectum consistent with proctitis-like presentation without other systemic issues pointing elsewhere initially suggests **Crohn's disease** given its involvement beyond just sigmoid area on colonoscopy reaching hepatic flexure—a hallmark feature often seen in Crohn's affecting upper tracts as well as lower ones over time due to its transmural nature compared solely ulcerative colitis which tends lower down.

**Answer: D) Crohn's disease**

2930  
29312932  
29332934  
29352936  
29372938  
29392940  
29412942  
29432944  
29452946  
29472948  
29492950  
29512952  
29532954  
29552956  
29572958  
29592960  
29612962  
29632964  
29652966  
29672968  
2969

2970  
2971

## Tables2Traces Reasoning

2972  
2973  
2974  
2975  
2976

Okay, let's tackle this question. So, the patient is a 41-year-old man with abdominal discomfort and cramping for four months. He also has grossly bloody stool and an urge to defecate. His history includes bulimia with laxative abuse several years ago, and he's lost about 5 pounds in the past month. Vital signs are within normal ranges except maybe blood pressure being slightly low.

2977  
2978  
2979  
2980  
2981

First off, I need to consider his symptoms: abdominal pain that's been going on for a while now, bloody stools (gross), urgency to defecate—all of which point towards some gastrointestinal issue causing inflammation or damage in the intestines. The fact that it started after he had issues with bulimia and laxatives makes me think there might be some underlying pathology related to those habits affecting his digestive system.

2982  
2983  
2984

Looking at the options:

2985  
2986  
2987

A) Ulcerative colitis: This is an inflammatory bowel disease characterized by continuous mucosal lesions throughout the colon and rectum usually starting from anus up but can extend proximal as well like here—up until hepatic flexure of colon according to exam results.

2988

B) Celiac disease: This affects small intestine primarily due to gluten sensitivity leading to villous atrophy but doesn't typically cause ulcerations as described here.

2989

C) Irritable bowel syndrome (IBS): Usually presents with alternating constipation/diarrhea without significant bleeding or structural changes; less likely given chronicity of symptoms.

2990  
2991  
2992

D) Crohn's disease: Also an inflammatory bowel disease but tends more towards transmural inflammation rather than just superficial ulcers like UC.

2993  
2994  
2995

So based on clinical presentation including duration of symptoms >3 months plus presence of both endoscopic findings suggests ulceration along entire length from rectum up into colon—**inflammatory nature consistent with either A or D.**

2996  
2997  
2998

But since Crohn's involves full thickness involvement unlike UC where it starts superficially then extends deeper over time—if they found only mucosal lesions so far does not rule out progression later—but initial presentation would lean toward UC given location mentioned in exam report "continuous mucosal lesions throughout rectum...to hepatic flexure"—which aligns better with typical distribution seen in ulcerative colitis compared

3000  
3001  
3002  
3003  
3004

Also considering his weight loss could indicate malnutrition secondary if dealing nutritional deficiencies due GI issues—which might be associated more commonly w/UC vs other conditions? Or perhaps cachexia-related weight loss sometimes happens when chronic diseases progress?

3005  
3006  
3007  
3008  
3009

The fact that he was diagnosed via Colonoscopy showing these features further supports diagnosis selection between A & D again favoring A because upper limit reached is still distal part near sigmoid area unless specified otherwise—and most cases present lower down first before moving upwards progressively over time).

3010  
3011  
3012  
3013  
3014  
3015  
3016  
3017  
3018  
3019  
3020  
3021  
3022  
3023

Additionally absence red flags pointing toward infectious etiology makes non-infectious causes likelier—he wouldn't have such sudden onset without previous exacerbating factors common among patients who develop IBD post-lax use/bulimic behaviors possibly contributing through altered gut microbiome composition etc., creating dysbiosis leading eventually immune-mediated response against epithelium.

So putting all together—the most likely diagnosis should be Ulcerative Colitis option A)

Answer: A